{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting wordCloud\n",
      "  Downloading https://files.pythonhosted.org/packages/4b/12/a489555dd7cdc8ee87e8dab071b6697271dfc57fc00fbe9b9e04c80354ea/wordcloud-1.9.3-cp37-cp37m-win_amd64.whl (300kB)\n",
      "Requirement already satisfied: numpy>=1.6.1 in c:\\anaconda3\\lib\\site-packages (from wordCloud) (1.21.5)\n",
      "Requirement already satisfied: matplotlib in c:\\anaconda3\\lib\\site-packages (from wordCloud) (3.1.0)\n",
      "Requirement already satisfied: pillow in c:\\anaconda3\\lib\\site-packages (from wordCloud) (9.5.0)\n",
      "Requirement already satisfied: cycler>=0.10 in c:\\anaconda3\\lib\\site-packages (from matplotlib->wordCloud) (0.10.0)\n",
      "Requirement already satisfied: kiwisolver>=1.0.1 in c:\\anaconda3\\lib\\site-packages (from matplotlib->wordCloud) (1.1.0)\n",
      "Requirement already satisfied: pyparsing!=2.0.4,!=2.1.2,!=2.1.6,>=2.0.1 in c:\\anaconda3\\lib\\site-packages (from matplotlib->wordCloud) (2.4.0)\n",
      "Requirement already satisfied: python-dateutil>=2.1 in c:\\anaconda3\\lib\\site-packages (from matplotlib->wordCloud) (2.8.0)\n",
      "Requirement already satisfied: six in c:\\anaconda3\\lib\\site-packages (from cycler>=0.10->matplotlib->wordCloud) (1.12.0)\n",
      "Requirement already satisfied: setuptools in c:\\anaconda3\\lib\\site-packages (from kiwisolver>=1.0.1->matplotlib->wordCloud) (41.0.1)\n",
      "Installing collected packages: wordCloud\n",
      "Successfully installed wordCloud-1.9.3\n"
     ]
    }
   ],
   "source": [
    "!pip install wordCloud"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [],
   "source": [
    "from wordcloud import WordCloud, STOPWORDS\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 308,
   "metadata": {},
   "outputs": [],
   "source": [
    "import csv\n",
    "import re\n",
    "import urllib\n",
    "from time import sleep\n",
    "\n",
    "\n",
    "\n",
    "def searchPubmed(query,work_id):\n",
    "    query=query.replace[' ','+']\n",
    "\n",
    "    result={'total-abstracts':0,'downloaded-abstracts':0, 'searchQuery':query,'id':work_id}\n",
    "\n",
    "    # common settings between esearch and efetch\n",
    "    base_url = 'http://eutils.ncbi.nlm.nih.gov/entrez/eutils/'\n",
    "    db = 'db=pubmed'\n",
    "\n",
    "    # esearch specific settings\n",
    "    search_eutil = 'esearch.fcgi?'\n",
    "    search_term = '&term=' + query\n",
    "    search_usehistory = '&usehistory=y'\n",
    "    search_rettype = '&rettype=json'\n",
    "    search_url = base_url+search_eutil+db+search_term+search_usehistory+search_rettype\n",
    "    f = urllib.request.urlopen(search_url)\n",
    "    search_data = f.read().decode('utf-8')\n",
    "    total_abstract_count = int(re.findall(\"<Count>(\\d+?)</Count>\",search_data)[0])\n",
    "    result['total-abstracts']=total_abstract_count\n",
    "    if total_abstract_count < 1:\n",
    "        result['fetch_data']=\"not found\"\n",
    "        return result\n",
    "    # obtain webenv and querykey settings for efetch command\n",
    "    fetch_webenv = \"&WebEnv=\" + re.findall (\"<WebEnv>(\\S+)<\\/WebEnv>\", search_data)[0]\n",
    "    fetch_querykey = \"&query_key=\" + re.findall(\"<QueryKey>(\\d+?)</QueryKey>\",search_data)[0]\n",
    "    # other efetch settings\n",
    "    fetch_eutil = 'efetch.fcgi?'\n",
    "    retmax = 10\n",
    "    retstart = 0\n",
    "    fetch_retstart = \"&retstart=\" + str(retstart)\n",
    "    fetch_retmax = \"&retmax=\" + str(retmax)\n",
    "    fetch_retmode = \"&retmode=text\"\n",
    "    fetch_rettype = \"&rettype=abstract\"\n",
    "    fetch_data=\"\"\n",
    "    # call efetch commands using a loop until all abstracts are obtained\n",
    "    run = True\n",
    "    all_abstracts = list()\n",
    "    loop_counter = 1\n",
    "    max_total =20\n",
    "    while run:\n",
    "        print(\"this is efetch run number \" + str(loop_counter))\n",
    "        loop_counter += 1\n",
    "        fetch_retstart = \"&retstart=\" + str(retstart)\n",
    "        fetch_retmax = \"&retmax=\" + str(retmax)\n",
    "        # create the efetch url\n",
    "        fetch_url = base_url+fetch_eutil+db+fetch_querykey+fetch_webenv+fetch_retstart+fetch_retmax+fetch_retmode+fetch_rettype\n",
    "        print(fetch_url)\n",
    "        # open the efetch url\n",
    "        f = urllib.request.urlopen (fetch_url)\n",
    "        fetch_data +=  f.read().decode('utf-8') + '\\n\\n\\n'\n",
    "\n",
    "        # wait 2 seconds so we don't get blocked\n",
    "        sleep(2)\n",
    "        # update retstart to download the next chunk of abstracts\n",
    "        retstart = retstart + retmax\n",
    "        if (retstart > total_abstract_count or retstart > max_total):\n",
    "            run = False\n",
    "        # split the data into individual abstracts\n",
    "    all_abstracts = fetch_data.split(\"\\n\\n\\n\")\n",
    "    print(\"a total of \" + str(len(all_abstracts)) + \" abstracts have been downloaded.\\n\")\n",
    "\n",
    "    abstracts=fetch_data.split('\\n\\n\\n')\n",
    "    abstracts_list=[]\n",
    "    for abstract in abstracts:\n",
    "        abstracts_list.append(abstract.split('\\n\\n'))\n",
    "    abstracts_list.pop()\n",
    "    result['downloaded-abstracts']=len(abstracts)-1\n",
    "\n",
    "    df=pd.DataFrame(abstracts_list)\n",
    "    df[0] = df[0].apply(remove_index)\n",
    "    df['doi'] = df.apply(find_doi, axis=1)\n",
    "    for i in range(0,df.shape[0]):\n",
    "        df.iloc[i,4]=df.iloc[i,4].lstrip()\n",
    "        if(df.iloc[i,4].startswith('Comment') or df.iloc[i,4].startswith('Erratum') or df.iloc[i,4].startswith('Update') or df.iloc[i,4].startswith('Author')):\n",
    "            df.iloc[i,4]=df.iloc[i,5]\n",
    "    createWordCloud(df.iloc[:,4])\n",
    "    new_df = df[[0,1,2,3,4,'doi']].rename(columns={0: 'Journal', 1: 'Title', 2: 'Author', 3: 'Author Info', 4: 'Abstract'})\n",
    "    dictdf=new_df.to_dict()\n",
    "    new_df.to_excel(work_id+'.xlsx',index=False)\n",
    "    result['dict']=dictdf\n",
    "    result['img']=work_id+'.png'\n",
    "    return result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 309,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "'builtin_function_or_method' object is not subscriptable",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-309-7bc8ec2d8b52>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[1;32m----> 1\u001b[1;33m \u001b[0mres\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0msearchPubmed\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'multiple myeloma related mirna'\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;34m'jckwdncwcbj'\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;32m<ipython-input-308-413bb9f0508b>\u001b[0m in \u001b[0;36msearchPubmed\u001b[1;34m(query, work_id)\u001b[0m\n\u001b[0;32m      8\u001b[0m \u001b[1;32mdef\u001b[0m \u001b[0msearchPubmed\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mquery\u001b[0m\u001b[1;33m,\u001b[0m\u001b[0mwork_id\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      9\u001b[0m     \u001b[0mresult\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;33m{\u001b[0m\u001b[1;34m'total-abstracts'\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;34m'downloaded-abstracts'\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m'searchQuery'\u001b[0m\u001b[1;33m:\u001b[0m\u001b[0mquery\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;34m'id'\u001b[0m\u001b[1;33m:\u001b[0m\u001b[0mwork_id\u001b[0m\u001b[1;33m}\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 10\u001b[1;33m     \u001b[0mquery\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mquery\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mreplace\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;34m' '\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;34m'+'\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     11\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     12\u001b[0m     \u001b[1;31m# common settings between esearch and efetch\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mTypeError\u001b[0m: 'builtin_function_or_method' object is not subscriptable"
     ]
    }
   ],
   "source": [
    "res=searchPubmed('multiple myeloma related mirna','jckwdncwcbj')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 306,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'total-abstracts': 3,\n",
       " 'downloaded-abstracts': 4,\n",
       " 'fetch_data': '',\n",
       " 'searchQuery': 'bortezomib+resistance+mirna+30',\n",
       " 'dict': {'Journal': {0: 'Hematology. 2022 Dec;27(1):596-602. doi: 10.1080/16078454.2022.2072062.',\n",
       "   1: 'Tumour Biol. 2015 Nov;36(11):8545-52. doi: 10.1007/s13277-015-3600-2. Epub\\n2015  Jun 2.',\n",
       "   2: 'Oncogene. 2011 Jun 2;30(22):2587-94. doi: 10.1038/onc.2010.634. Epub 2011 Feb\\n7.'},\n",
       "  'Title': {0: 'Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for \\nbortezomib response and prognosis in multiple myeloma patients.',\n",
       "   1: 'Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as \\nbiomarkers for multiple myeloma.',\n",
       "   2: 'Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.'},\n",
       "  'Author': {0: 'Zhou F(1), Guo L(1).',\n",
       "   1: 'Peng J(1), Thakur A(2)(3), Zhang S(2), Dong Y(4), Wang X(5), Yuan R(5), Zhang \\nK(5), Guo X(6).',\n",
       "   2: 'Sotillo E(1), Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, \\nThomas-Tikhonenko A.'},\n",
       "  'Author Info': {0: \"Author information:\\n(1)Department of Hematology, The Central Hospital of Wuhan, Tongji Medical \\nCollege, Huazhong University of Science and Technology, Wuhan, People's Republic \\nof China.\",\n",
       "   1: \"Author information:\\n(1)Medical College of Xi'an Jiaotong University, Xi'an Jiaotong University, \\nXi'an, People's Republic of China.\\n(2)Department of Respiratory and Critical Care Medicine, The First Affiliated \\nHospital, Medical College of Xi'an Jiaotong University, Xi'an Jiaotong \\nUniversity, Xi'an, People's Republic of China.\\n(3)Department of Internal Medicine, Life Guard Hospital, Biratnagar, Nepal.\\n(4)Clinical Laboratory of 521 Hospital of the Ordinance Industry, Zhangba East \\nStreet, Xi'an, 710065, People's Republic of China.\\n(5)Department of Clinical Laboratory, The First Affiliated Hospital, Medical \\nCollege of Xi'an Jiaotong University, Xi'an Jiaotong University, 277 Yanta West \\nStreet, Xi'an, 710061, Shaanxi Province, People's Republic of China.\\n(6)Department of Clinical Laboratory, The First Affiliated Hospital, Medical \\nCollege of Xi'an Jiaotong University, Xi'an Jiaotong University, 277 Yanta West \\nStreet, Xi'an, 710061, Shaanxi Province, People's Republic of China. \\nguox9512@163.com.\",\n",
       "   2: \"Author information:\\n(1)Division of Cancer Pathobiology, Department of Pathology & Laboratory \\nMedicine, The Children's Hospital of Philadelphia, PA 19104-4399, USA.\"},\n",
       "  'Abstract': {0: 'OBJECTIVE: Long non-coding RNA ANGPTL1-3 (lnc-ANGPTL1-3) is previously observed \\nto induce bortezomib resistance via targeting microRNA-30a (miR-30a) in multiple \\nmyeloma (MM). Hence, this study aimed to further explore the relationship \\nbetween lnc-ANGPTL1-3 and miR-30a and their linkage with disease properties and \\nprognosis in bortezomib-treated MM patients.\\nMETHODS: Fifty-nine MM patients underwent treatment with the bortezomib-based \\nregimen, and 30 healthy donors were consecutively enrolled. Bone marrow samples \\nwere collected from MM patients (before therapy) and healthy donors; then, \\nplasma cells were separated for lnc-ANGPTL1-3 and miR-30a detection by RT-qPCR. \\nThen treatment response, progression-free survival (PFS), and overall survival \\n(OS) of MM patients were assessed.\\nRESULTS: Lnc-ANGPTL1-3 was upregulated while miR-30a was downregulated in MM \\npatients compared to healthy donors (both P\\u2009<\\u20090.001), then a negative \\ncorrelation between lnc-ANGPTL1-3 and miR-30a was found in MM patients \\n(P\\u2009<\\u20090.001) instead of in health donors (P\\u2009=\\u20090.188). In MM patients, \\nlnc-ANGPTL1-3 correlated with increased t (4;14) (P\\u2009=\\u20090.033), Del (17p) \\n(P\\u2009=\\u20090.018), ISS stage (P\\u2009=\\u20090.020), R-ISS stage (P\\u2009=\\u20090.025) but not t (14;16) \\n(P\\u2009=\\u20090.255) or Durie-Salmon stage (P\\u2009=\\u20090.186); while miR-30a only related to \\ndecreased t (14;16) (P\\u2009=\\u20090.025) and R-ISS stage (P\\u2009=\\u20090.006). Besides, \\nlnc-ANGPTL1-3 predicted lower complete response (CR) (P\\u2009=\\u20090.034), poor PFS \\n(P\\u2009=\\u20090.016) and OS (P\\u2009=\\u20090.041) but not objective response rate (ORR) \\n(P\\u2009=\\u20090.128). However, miR-30a forecasted higher CR (P\\u2009=\\u20090.013), prolonged PFS \\n(P\\u2009=\\u20090.014), and OS (P\\u2009=\\u20090.045) but not ORR (P\\u2009=\\u20090.407).\\nCONCLUSION: Lnc-ANGPTL1-3 negative correlates with miR-30a, which links with key \\ncytogenetic features, ISS/R-ISS stage, and prognosis in MM patients who \\nunderwent treatment of bortezomib-based regimen.',\n",
       "   1: \"Multiple myeloma (MM) is characterized by clonal proliferation of malignant \\nplasma cells in the bone marrow. The anti-tumor activity of bortezomib (a \\nproteosome inhibitor) in MM is challenged by emergence of drug resistance. \\nMicroRNAs (miR) regulate and orchestrate multiple cellular pathways. We \\ninvestigate the contribution miR-181a and miR-20a expressions' on cell \\nproliferation and apoptosis in RPMI8226 cell line and their influence on \\nbortezomib treatment. RNA isolation, quantitative real-time PCR (qRT-PCR), cell \\nproliferation assay, cell cycle analysis, and cell apoptosis assay were done. \\nStatistical analysis was performed using SPSS 17.0 software (SPSS, Chicago, IL, \\nUSA). P values of less than 0.05 were considered statistically significant. \\nRPMI8226 cells seeded in 96-well plates and treated for 24 h with different \\nconcentrations of bortezomib showed dose-dependent growth inhibition; expression \\nof both miR-181a and miR-20a were inhibited by bortezomib. We found decrease of \\nmiR-181a (60%) and miR-20a (30%) in cells transfected with 20-nM inhibitor. A \\nrelative increase of 14-fold in miR-181a and 11-fold in miR-20a was observed in \\ncells transfected with mimics of the same concentration. Transient low \\nexpression of miR-181a/20a inhibited proliferation at day 4, and overexpression \\nof miR-181a promoted proliferation. Cells transfected with miR-181a/20a \\ninhibitor within day 4 showed lower survival rate, and low expression of \\nmiR-181a on the fourth day after transfection promoted apoptosis. Our findings \\nsuggest that miR-181a/20a has a higher expression in MM. miR-181-a expression is \\nproportional to MM tumor burden and could be a biomaker for monitoring \\ntreatment. miR-20a shows the potential of a diagnostic biomarker.\",\n",
       "   2: \"Downregulation of microRNA-34a by Myc is known to be essential for tumorigenesis \\nand improve tumor-cell survival. Conversely, upregulation of miR-34a by p53 is \\nthought to enhance its acetylation and activity and contribute to the \\npro-apoptotic effects of this tumor suppressor. We sought to determine whether \\nrestoration of miR-34a levels in B-lymphoid cells with Myc overexpression would \\naid therapeutic apoptosis. Unexpectedly, delivery of miR-34a, which doesn't \\ntarget p53 directly, severely compromised steady-state p53 levels. This effect \\nwas preceded and mediated by direct targeting of Myc, which sustained p53 \\nprotein levels via the Arf-Hdm2 pathway. As a result, in the presence of Myc, \\nmiR-34a inhibited p53-dependent bortezomib-induced apoptosis as efficiently as \\nanti-p53 small interfering RNA. Conversely, inhibition of miR-34a using \\nantisense RNA sensitized lymphoma cells to therapeutic apoptosis. Thus, in \\ntumors with deregulated Myc expression, miR-34a confers drug resistance and \\ncould be considered a therapeutic target.\"},\n",
       "  'doi': {0: 'DOI: 10.1080/16078454.2022.2072062\\nPMID: 35617291 [Indexed for MEDLINE]',\n",
       "   1: 'DOI: 10.1007/s13277-015-3600-2\\nPMID: 26032093 [Indexed for MEDLINE]',\n",
       "   2: 'DOI: 10.1038/onc.2010.634\\nPMCID: PMC3128883\\nPMID: 21297663 [Indexed for MEDLINE]'}},\n",
       " 'img': 'sample.png'}"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "res"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 301,
   "metadata": {},
   "outputs": [],
   "source": [
    "new_df = df[[0,1,2,3,4,'doi']].rename(columns={0: 'Journal', 1: 'Title', 2: 'Author', 3: 'Author Info', 4: 'Abstract'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 303,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Journal': {0: 'Leuk Lymphoma. 2023 Nov 10:1-8. doi: 10.1080/10428194.2023.2278431. Online\\nahead  of print.',\n",
       "  1: 'Cells. 2023 Sep 7;12(18):2226. doi: 10.3390/cells12182226.',\n",
       "  2: 'Cancer Res. 2023 Sep 26. doi: 10.1158/0008-5472.CAN-23-0189. Online ahead of \\nprint.',\n",
       "  3: 'Biochem Genet. 2023 Oct;61(5):1898-1916. doi: 10.1007/s10528-023-10356-2. Epub\\n 2023 Mar 7.',\n",
       "  4: 'Biomed Pharmacother. 2023 May;161:114432. doi: 10.1016/j.biopha.2023.114432. \\nEpub 2023 Feb 24.',\n",
       "  5: 'Pharmaceuticals (Basel). 2023 Jan 12;16(1):111. doi: 10.3390/ph16010111.',\n",
       "  6: 'Leuk Res. 2022 Dec;123:106967. doi: 10.1016/j.leukres.2022.106967. Epub 2022\\nOct  6.',\n",
       "  7: 'Anticancer Drugs. 2022 Oct 1;33(9):893-902. doi: 10.1097/CAD.0000000000001378.\\n Epub 2022 Sep 14.',\n",
       "  8: 'Hematology. 2022 Dec;27(1):596-602. doi: 10.1080/16078454.2022.2072062.',\n",
       "  9: 'Cancers (Basel). 2022 Mar 27;14(7):1700. doi: 10.3390/cancers14071700.',\n",
       "  10: 'Leuk Res. 2022 Mar;114:106785. doi: 10.1016/j.leukres.2022.106785. Epub 2022\\nJan  7.',\n",
       "  11: 'Chemotherapy. 2022;67(2):110-122. doi: 10.1159/000518936. Epub 2022 Jan 18.',\n",
       "  12: 'J Pathol. 2022 Apr;256(4):402-413. doi: 10.1002/path.5852. Epub 2022 Jan 21.',\n",
       "  13: 'Front Oncol. 2021 Sep 22;11:720261. doi: 10.3389/fonc.2021.720261. eCollection\\n 2021.',\n",
       "  14: 'Anticancer Drugs. 2022 Jan 1;33(1):e145-e154. doi:\\n10.1097/CAD.0000000000001166.',\n",
       "  15: 'Curr Med Chem. 2021 Oct 25;28(33):6753-6772. doi: \\n10.2174/0929867328666210504104419.',\n",
       "  16: 'Onco Targets Ther. 2021 Jan 15;14:455-467. doi: 10.2147/OTT.S286751.\\neCollection  2021.',\n",
       "  17: 'J Cell Biochem. 2021 Apr;122(3-4):305-314. doi: 10.1002/jcb.29684. Epub 2021\\nJan  8.',\n",
       "  18: 'Cell Biol Int. 2021 May;45(5):965-975. doi: 10.1002/cbin.11540. Epub 2021 Jan \\n15.',\n",
       "  19: 'Haematologica. 2020 Dec 1;105(12):2813-2823. doi:\\n10.3324/haematol.2019.227579.',\n",
       "  20: 'Eur J Pharmacol. 2021 Jan 15;891:173752. doi: 10.1016/j.ejphar.2020.173752.\\nEpub  2020 Nov 28.',\n",
       "  21: 'Cell Cycle. 2020 Dec;19(23):3289-3302. doi: 10.1080/15384101.2020.1839701.\\nEpub  2020 Nov 1.',\n",
       "  22: 'Life Sci. 2020 Dec 1;262:118506. doi: 10.1016/j.lfs.2020.118506. Epub 2020 Oct\\n 5.',\n",
       "  23: 'Cancers (Basel). 2020 Sep 9;12(9):2569. doi: 10.3390/cancers12092569.',\n",
       "  24: 'Cancer Manag Res. 2020 Mar 20;12:2109-2118. doi: 10.2147/CMAR.S241089. \\neCollection 2020.',\n",
       "  25: 'Cancer Lett. 2020 Jun 28;480:29-38. doi: 10.1016/j.canlet.2020.03.020. Epub\\n2020  Mar 24.',\n",
       "  26: 'BMC Cancer. 2019 Oct 21;19(1):975. doi: 10.1186/s12885-019-6151-x.',\n",
       "  27: 'Cell Cycle. 2019 Jul;18(14):1660-1669. doi: 10.1080/15384101.2019.1632138.\\nEpub  2019 Jun 20.',\n",
       "  28: 'Biochem Biophys Res Commun. 2019 Jul 5;514(4):1140-1146. doi: \\n10.1016/j.bbrc.2019.05.078. Epub 2019 May 15.',\n",
       "  29: 'PLoS One. 2019 May 7;14(5):e0216400. doi: 10.1371/journal.pone.0216400. \\neCollection 2019.'},\n",
       " 'Title': {0: 'Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma \\npatients treated with bortezomib-based regimens - pilot study.',\n",
       "  1: 'GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma.',\n",
       "  2: 'Hypoxic bone marrow stromal cells secrete miR-140-5p and miR-28-3p target SPRED1 \\nto confer drug resistance in multiple myeloma.',\n",
       "  3: 'Bioinformatic Analysis of miR-200b/429 and Hub Gene Network in Cervical Cancer.',\n",
       "  4: 'miR-33b in human cancer: Mechanistic and clinical perspectives.',\n",
       "  5: 'Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of \\nEmerging Technologies.',\n",
       "  6: 'LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in \\nmultiple myeloma.',\n",
       "  7: 'Circ_0005615 contributes to the progression and Bortezomib resistance of \\nmultiple myeloma by sponging miR-185-5p and upregulating IRF4.',\n",
       "  8: 'Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for \\nbortezomib response and prognosis in multiple myeloma patients.',\n",
       "  9: 'Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential \\nTherapeutic Targets in Multiple Myeloma.',\n",
       "  10: 'MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 \\nexpression in a MEAF6-dependent manner.',\n",
       "  11: 'miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on \\nNon-Small-Cell Lung Cancer by Inhibiting CCND1.',\n",
       "  12: 'Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by \\nexpression of lncRNAs.',\n",
       "  13: 'Bortezomib Inhibits Multiple Myeloma Cells by Transactivating ATF3 to Trigger \\nmiR-135a-5p- Dependent Apoptosis.',\n",
       "  14: 'Circular RNA circ-CCT3 promotes bortezomib resistance in multiple myeloma via \\nmodulating miR-223-3p/BRD4 axis.',\n",
       "  15: 'MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic \\nSignificance.',\n",
       "  16: 'MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib \\nSensitivity in Multiple Myeloma Cells by Targeting Heparanase.',\n",
       "  17: 'miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.',\n",
       "  18: 'Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to \\nbortezomib.',\n",
       "  19: 'Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor \\ngrowth through induction of phagocytosis and apoptosis in multiple myeloma.',\n",
       "  20: 'Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib \\nresistance in human multiple myeloma cells.',\n",
       "  21: 'Depletion of circ_0007841 inhibits multiple myeloma development and BTZ \\nresistance via miR-129-5p/JAG1 axis.',\n",
       "  22: 'CircRNA ITCH increases bortezomib sensitivity through regulating the \\nmiR-615-3p/PRKCD axis in multiple myeloma.',\n",
       "  23: 'The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to \\nBortezomib-Based Therapy in Multiple Myeloma Patients.',\n",
       "  24: 'hsa_circRNA_101237: A Novel Diagnostic and Prognostic Biomarker and Potential \\nTherapeutic Target for Multiple Myeloma.',\n",
       "  25: 'MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect \\nof standard therapy against drug-resistant multiple myeloma.',\n",
       "  26: 'Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow \\nstroma-mediated drug resistance in multiple myeloma cells.',\n",
       "  27: 'miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via \\nsuppressing APE1.',\n",
       "  28: 'Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by \\nsponging miR-30a-3p to activate c-Maf expression.',\n",
       "  29: 'MicroRNAs as possible indicators of drug sensitivity in breast cancer cell \\nlines.'},\n",
       " 'Author': {0: 'Puła A(1)(2), Robak T(1)(3), Dróżdż I(4), Stawiski K(5), Rycerz A(5), Misiewicz \\nM(1), Robak P(1)(2).',\n",
       "  1: 'Gallo Cantafio ME(1), Torcasio R(1)(2), Scionti F(3), Mesuraca M(1), Ronchetti \\nD(4), Pistoni M(5), Bellizzi D(6), Passarino G(6), Morelli E(7), Neri A(8), \\nViglietto G(1), Amodio N(1).',\n",
       "  2: 'Zhang H(1), Du Z(2), Tu C(2), Zhou X(1), Menu E(3), Wang J(2).',\n",
       "  3: 'Shukla V(1), Mallya S(2), Adiga D(1), Sriharikrishnaa S(1), Chakrabarty S(1)(3), \\nKabekkodu SP(4)(5).',\n",
       "  4: 'Zhang W(1), Jiang B(2), Zhu H(3), Cheng A(2), Li C(1), Huang H(1), Li X(3), \\nKuang Y(4).',\n",
       "  5: 'Kozalak G(1)(2), Bütün İ(1), Toyran E(1), Koşar A(1)(2)(3).',\n",
       "  6: 'Zang X(1), Wang J(1), Xia Y(1), Li J(1), Chen L(1), Gu Y(2), Shen X(3).',\n",
       "  7: 'Fu C(1), Wang J, Hu M, Zhou W.',\n",
       "  8: 'Zhou F(1), Guo L(1).',\n",
       "  9: 'Allegra A(1), Cicero N(2), Tonacci A(3), Musolino C(1), Gangemi S(4).',\n",
       "  10: 'Liu Y(1), Cheng P(1), Zhao W(1), Zhu L(2), Sui J(3), Dai Y(1), Lai Y(4).',\n",
       "  11: 'Wang WH(1), Zhan JM(1), Tang YL(1), Zhou N(1), Liu WY(2), Jiang DW(1).',\n",
       "  12: 'Saltarella I(1), Lamanuzzi A(1), Desantis V(1)(2), Di Marzo L(1), Melaccio A(1), \\nCurci P(3), Annese T(4), Nico B(4), Solimando AG(1)(5), Bartoli G(1), Tolomeo \\nD(6), Storlazzi CT(6), Mariggiò MA(7), Ria R(1), Musto P(3)(8), Vacca A(#)(1), \\nFrassanito MA(#)(7).',\n",
       "  13: 'Lai X(1), Huang C(2), Nie X(3), Chen Q(1), Tang Y(1), Fu X(4), Lin Y(1), Nie \\nC(1), Xu X(1), Wang X(1), Chen R(1), Chen Z(3).',\n",
       "  14: 'Liu D(1), Wang Y, Li H, Peng S, Tan H, Huang Z.',\n",
       "  15: 'Puła A(1), Robak P(1), Robak T(1).',\n",
       "  16: 'Rodrigues-Junior DM(1)(2), Pelarin MFA(1), Nader HB(1), Vettore AL(3), Pinhal \\nMAS(1)(4).',\n",
       "  17: 'Chen H(1), Cao W(2), Chen J(1), Liu D(1), Zhou L(1), Du F(1), Zhu F(3).',\n",
       "  18: 'Tang JX(1), Chen Q(1), Li Q(2), He YH(2), Xiao D(2).',\n",
       "  19: 'Rastgoo N(1), Wu J(1), Liu A(2), Pourabdollah M(1), Atenafu EG(3), Reece D(4), \\nChen W(2), Chang H(5).',\n",
       "  20: 'Che F(1), Ye X(2), Wang Y(2), Ma S(2), Wang X(2).',\n",
       "  21: 'Wang Y(1), Lin Q(2), Song C(1), Ma R(1), Li X(1).',\n",
       "  22: 'Liu J(1), Du F(2), Chen C(1), Li D(1), Chen Y(1), Xiao X(1), Hou X(3).',\n",
       "  23: 'Robak P(1), Dróżdż I(2), Jarych D(3), Mikulski D(4), Węgłowska E(3), \\nSiemieniuk-Ryś M(5), Misiewicz M(5), Stawiski K(4), Fendler W(4), Szemraj J(6), \\nSmolewski P(1), Robak T(5).',\n",
       "  24: 'Liu X(#)(1), Tang H(#)(1), Liu J(1), Wang X(2).',\n",
       "  25: 'Zhang L(1), Rastgoo N(1), Wu J(1), Zhang M(1), Pourabdollah M(1), Zacksenhaus \\nE(1), Chen Y(2), Chang H(3).',\n",
       "  26: 'Abdi J(1), Rastgoo N(1), Chen Y(1), Chen GA(2), Chang H(3)(4).',\n",
       "  27: 'Yuan X(1), Ma R(1), Yang S(1), Jiang L(1), Wang Z(1), Zhu Z(1), Li H(2).',\n",
       "  28: 'Nian F(1), Zhu J(2), Chang H(3).',\n",
       "  29: 'Uhr K(1), Prager-van der Smissen WJC(1), Heine AAJ(1), Ozturk B(1), van \\nJaarsveld MTM(1), Boersma AWM(1), Jager A(1), Wiemer EAC(1), Smid M(1), Foekens \\nJA(1), Martens JWM(1).'},\n",
       " 'Author Info': {0: 'Author information:\\n(1)Department of Hematology, Medical University of Lodz, Lodz, Poland.\\n(2)Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland.\\n(3)Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland.\\n(4)Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland.\\n(5)Department of Biostatistics and Translational Medicine, Medical University of \\nLodz, Lodz, Poland.',\n",
       "  1: 'Author information:\\n(1)Department of Experimental and Clinical Medicine, Magna Graecia University, \\n88100 Catanzaro, Italy.\\n(2)Laboratory of Cellular and Molecular Cardiovascular Pathophysiology, \\nDepartment of Biology, Ecology and Earth Sciences (DiBEST), University of \\nCalabria, Arcavacata di Rende, 87036 Cosenza, Italy.\\n(3)Department of Medical and Surgical Science, University Magna Graecia, 88100 \\nCatanzaro, Italy.\\n(4)Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, \\nItaly.\\n(5)Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, \\n42123 Reggio Emilia, Italy.\\n(6)Department of Biology, Ecology and Earth Sciences, University of Calabria, \\n87036 Rende, Italy.\\n(7)Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, \\nDana-Farber Cancer Institute, Boston, MA 02215, USA.\\n(8)Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio \\nEmilia, Italy.',\n",
       "  2: 'Author information:\\n(1)Guangzhou Medical University, China.\\n(2)Guangzhou Medical University, Guangzhou, China.\\n(3)Vrije Universiteit Brussel, Brussel, Belgium.',\n",
       "  3: 'Author information:\\n(1)Department of Cell and Molecular Biology, Manipal School of Life Sciences, \\nManipal Academy of Higher Education, Manipal, India.\\n(2)Department of Bioinformatics, Manipal School of Life Sciences, Manipal \\nAcademy of Higher Education, Manipal, India.\\n(3)Center for DNA Repair and Genome Stability (CDRGS), Manipal Academy of Higher \\nEducation, Manipal, Karnataka, India.\\n(4)Department of Cell and Molecular Biology, Manipal School of Life Sciences, \\nManipal Academy of Higher Education, Manipal, India. shama.prasada@manipal.edu.\\n(5)Center for DNA Repair and Genome Stability (CDRGS), Manipal Academy of Higher \\nEducation, Manipal, Karnataka, India. shama.prasada@manipal.edu.',\n",
       "  4: 'Author information:\\n(1)Department of Neurosurgery, National Clinical Research Center for Geriatric \\nDisorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, \\n410008, China; Cancer Research Institute, School of Basic Medical Science, \\nCentral South University, Changsha, Hunan Province, 410008, China.\\n(2)Cancer Research Institute, Hengyang Medical School, University of South \\nChina, Hengyang, Hunan Province, 421001, China.\\n(3)Changsha Kexin Cancer Hospital, Changsha, Hunan Province 410205, China.\\n(4)Department of Neurosurgery, National Clinical Research Center for Geriatric \\nDisorders, Xiangya Hospital, Central South University, Changsha, Hunan Province, \\n410008, China; Cancer Research Institute, School of Basic Medical Science, \\nCentral South University, Changsha, Hunan Province, 410008, China. Electronic \\naddress: philkyr@163.com.',\n",
       "  5: 'Author information:\\n(1)Faculty of Engineering and Natural Science, Sabancı University, Istanbul \\n34956, Turkey.\\n(2)Center of Excellence for Functional Surfaces and Interfaces for Nano \\nDiagnostics (EFSUN), Sabancı University, Istanbul 34956, Turkey.\\n(3)Turkish Academy of Sciences (TÜBA), Çankaya, Ankara 06700, Turkey.',\n",
       "  6: 'Author information:\\n(1)Department of Hematology, the First Affiliated Hospital of Nanjing Medical \\nUniversity, Jiangsu Province Hospital, Collaborative Innovation Center for \\nCancer Personalized Medicine, Nanjing 210029, China.\\n(2)Department of Geriatrics, the Second Hospital of Nanjing, Nanjing University \\nof Chinese Medicine, Nanjing 210003, China. Electronic address: \\nguyan703@foxmail.com.\\n(3)Department of Hematology, the First Affiliated Hospital of Nanjing Medical \\nUniversity, Jiangsu Province Hospital, Collaborative Innovation Center for \\nCancer Personalized Medicine, Nanjing 210029, China. Electronic address: \\nruxiaoguo1992@163.com.',\n",
       "  7: \"Author information:\\n(1)Department of Hematology, The First Affiliated Hospital of Hainan Medical \\nUniversity, People's Republic of China.\",\n",
       "  8: \"Author information:\\n(1)Department of Hematology, The Central Hospital of Wuhan, Tongji Medical \\nCollege, Huazhong University of Science and Technology, Wuhan, People's Republic \\nof China.\",\n",
       "  9: 'Author information:\\n(1)Department of Human Pathology in Adulthood and Childhood \"Gaetano Barresi\", \\nDivision of Hematology, University of Messina, 98125 Messina, Italy.\\n(2)Department of Biomedical and Dental Sciences and Morphofunctional Imaging, \\nUniversity of Messina, 98125 Messina, Italy.\\n(3)Clinical Physiology Institute, National Research Council of Italy (IFC-CNR), \\n56124 Pisa, Italy.\\n(4)Allergy and Clinical Immunology Unit, Department of Clinical and Experimental \\nMedicine, University of Messina, 98125 Messina, Italy.',\n",
       "  10: 'Author information:\\n(1)Department of Hematology, the First Affiliated Hospital of Guangxi Medical \\nUniversity, Nanning, Guangxi 530021, China.\\n(2)Department of Health Management, the First Affiliated Hospital of Guangxi \\nMedical University, Nanning, Guangxi 530021, China.\\n(3)Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi \\nMedical University, Nanning, Guangxi 530021, China.\\n(4)Department of Hematology, the First Affiliated Hospital of Guangxi Medical \\nUniversity, Nanning, Guangxi 530021, China. Electronic address: \\nlaiyongrong@263.net.',\n",
       "  11: 'Author information:\\n(1)Department of Thoracic Surgery, Institute of Fudan-Minhang Academic Health \\nSystem, Minhang Hospital, Fudan University, Shanghai, China.\\n(2)Department of General Surgery, Institute of Fudan-Minhang Academic Health \\nSystem, Minhang Hospital, Fudan University, Shanghai, China.',\n",
       "  12: \"Author information:\\n(1)Department of Biomedical Sciences and Human Oncology, Unit of Internal \\nMedicine 'Guido Baccelli', University of Bari Medical School, Bari, Italy.\\n(2)Department of Biomedical Sciences and Human Oncology, Pharmacology Section, \\nUniversity of Bari Medical School, Bari, Italy.\\n(3)Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, \\nItaly.\\n(4)Department of Basic Medical Sciences, Neurosciences and Sensory Organs, \\nSection of Human Anatomy and Histology, University of Bari Medical School, Bari, \\nItaly.\\n(5)IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.\\n(6)Department of Biology, University of Bari 'Aldo Moro', Bari, Italy.\\n(7)Department of Biomedical Sciences and Human Oncology, Unit of General \\nPathology, University of Bari 'Aldo Moro', Bari, Italy.\\n(8)Department of Emergency and Organ Transplantation, 'Aldo Moro', University \\nSchool of Medicine, Bari, Italy.\\n(#)Contributed equally\",\n",
       "  13: 'Author information:\\n(1)Department of Hematology and Rheumatism, Ningde Municipal Hospital Affiliated \\nto Ningde Normal University, Ningde, China.\\n(2)Department of Medical Oncology and Radiotherapy, Ningde Municipal Hospital \\nAffiliated to Ningde Normal University, Ningde, China.\\n(3)Department of Pharmacy, Ningde Municipal Hospital, Affiliated to Ningde \\nNormal University, Ningde, China.\\n(4)Central Laboratory, Ningde Municipal Hospital Affiliated to Ningde Normal \\nUniversity, Ningde, China.',\n",
       "  14: 'Author information:\\n(1)Department of Hematology, the First Affiliated Hospital of Guangzhou Medical \\nUniversity, Guangzhou 510120, Guangdong Province, China.',\n",
       "  15: 'Author information:\\n(1)Department of Hematology, Medical University of Lodz, Copernicus Memorial \\nHospital, 93-510 Lodz Ul, Ciolkowskiego 2, Poland.',\n",
       "  16: 'Author information:\\n(1)Department of Biochemistry, Universidade Federal de São Paulo (UNIFESP), São \\nPaulo, Brazil.\\n(2)Institute of Medical Biochemistry and Microbiology, Uppsala University, \\nUppsala, Sweden.\\n(3)Department of Biological Science, Universidade Federal de São Paulo \\n(UNIFESP), Diadema, Brazil.\\n(4)Department of Biochemistry, Faculdade de Medicina do ABC, Santo André, \\nBrazil.',\n",
       "  17: \"Author information:\\n(1)Department of Hematology, Shenzhen Luohu People's Hospital, The Third \\nAffiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.\\n(2)Department of Pharmacy, Shenzhen Luohu People's Hospital, The Third \\nAffiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.\\n(3)Cognitive Impairment Ward of Neurology Department, Shenzhen Luohu People's \\nHospital, The Third Affiliated Hospital of Shenzhen University, Shenzhen, \\nGuangdong, China.\",\n",
       "  18: 'Author information:\\n(1)Department of Hematology, The Third Affiliated Hospital of Southern Medical \\nUniversity, Guangzhou, China.\\n(2)Department of Rehabilitation, The First Affiliated Hospital of Jinan \\nUniversity, Guangzhou, China.',\n",
       "  19: 'Author information:\\n(1)Department of Laboratory Medicine and Pathobiology, University of Toronto, \\nCanada.\\n(2)Department of Hematology, Beijing Chaoyang Hospital, Capital University \\nBeijing, China.\\n(3)Department of Biostatistics, University Health Network, Toronto, Canada.\\n(4)Department of Hematology and Medical Oncology, University Health Network, \\nToronto, Canada.\\n(5)University Health Network, University of Toronto, Toronto, Canada.',\n",
       "  20: \"Author information:\\n(1)Department of Hematology, Sichuan Provincial People's Hospital, University of \\nElectronic Science and Technology of China, Chinese Academy of Sciences Sichuan \\nTranslational Medicine Research Hospital, Chengdu, 610072, Sichuan, China. \\nElectronic address: Chefeifei2@126.com.\\n(2)Department of Hematology, Dongli Medical District of Sichuan Provincial \\nPeople's Hospital, University of Electronic Science and Technology of China, \\nChinese Academy of Sciences Sichuan Translational Medicine Research Hospital, \\nChengdu, 610051, Sichuan, China.\",\n",
       "  21: 'Author information:\\n(1)Department of Hematology, The Fifth Affiliated Hospital of Zhengzhou \\nUniversity , Zhengzhou, Henan, China.\\n(2)Department of Hematology, Henan Cancer Hospital , Zhengzhou, Henan, China.',\n",
       "  22: \"Author information:\\n(1)Orthopaedics Department, The First Affiliated Hospital of Henan University, \\nKaifeng, Henan, China.\\n(2)Department of Hematology and Oncology, No. 988 Hospital of Joint Logistic \\nSupport Force of the Chinese People's Liberation Army, Zhengzhou, Henan \\nProvince, China.\\n(3)Ultrasound Department, The First Affiliated Hospital of Henan University, \\nKaifeng, Henan, China. Electronic address: dong2848fw@163.com.\",\n",
       "  23: 'Author information:\\n(1)Department of Experimental Hematology, Medical University of Lodz, 93-510 \\nLodz, Poland.\\n(2)Department of Clinical Genetics, Medical University of Lodz, 92-213 Lodz, \\nPoland.\\n(3)Laboratory of Personalized Medicine, Bionanopark, Lodz, 93-465 Lodz, Poland.\\n(4)Department of Biostatistics and Translational Medicine, Medical University of \\nLodz, 92-215 Lodz, Poland.\\n(5)Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.\\n(6)Department of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, \\nPoland.',\n",
       "  24: \"Author information:\\n(1)The Third Xiangya Hospital of Central South University, Changsha 410013, \\nPeople's Republic of China.\\n(2)Department of Hematology, First Affiliated Hospital of Anhui Medical \\nUniversity, Hefei 230022, People's Republic of China.\\n(#)Contributed equally\",\n",
       "  25: 'Author information:\\n(1)Department of Laboratory Medicine and Pathobiology, University of Toronto, \\nCanada.\\n(2)Department of Laboratory Medicine and Pathobiology, University of Toronto, \\nCanada; Department of Hematology, The Eighth Affiliated Hospital, Sun Yat-Sen \\nUniversity, Senzhen, China. Electronic address: cheny658@mail.sysu.edu.\\n(3)Department of Laboratory Medicine and Pathobiology, University of Toronto, \\nCanada. Electronic address: hong.chang@uhn.ca.',\n",
       "  26: 'Author information:\\n(1)Dept. of Laboratory Hematology, Laboratory Medicine Program, Toronto General \\nHospital, University Health Network, 200 Elizabeth Street, 11E-413, Toronto, \\nOntario, M5G 2C4, Canada.\\n(2)Department of Hematology/Oncology, First Affiliated Hospital, Nanchang \\nUniversity, Nanchang, China.\\n(3)Dept. of Laboratory Hematology, Laboratory Medicine Program, Toronto General \\nHospital, University Health Network, 200 Elizabeth Street, 11E-413, Toronto, \\nOntario, M5G 2C4, Canada. Hong.Chang@uhn.ca.\\n(4)Dept. of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, \\nCanada. Hong.Chang@uhn.ca.',\n",
       "  27: \"Author information:\\n(1)a Department of Hematology, Henan Key Laboratory for Hematology, Henan \\nProvincial People's Hospital , People's Hospital of Zhengzhou University , \\nZhengzhou , Henan , China.\\n(2)b Department of Neurosurgery , the First Affiliated Hospital of Zhengzhou \\nUniversity , Zhengzhou , Henan , China.\",\n",
       "  28: \"Author information:\\n(1)School of Clinical Medicine, Bengbu Medical College, Bengbu, Anhui Province, \\nPR China.\\n(2)First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, \\nPR China.\\n(3)First People's Hospital of Changzhou, Changzhou, Jiangsu Province, PR China. \\nElectronic address: hainingc0123@163.com.\",\n",
       "  29: 'Author information:\\n(1)Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC \\nCancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.'},\n",
       " 'Abstract': {0: 'Despite advances in multiple myeloma (MM) treatment, drug resistance remains a \\nclinical challenge. We aimed to develop a prognostic model for bortezomib \\nresistance based on miRNA expression profiling. The study included 40 previously \\nuntreated MM patients receiving bortezomib-based regimens (20 \\ntreatment-sensitive, 20 resistant). Pretreatment venous blood samples were \\nanalyzed for miRNA expression. Differential expression analysis revealed \\nupregulated miR-27b-3p (FC 1.45, p\\u2009=\\u20090.017) and let-7b-5p (FC 1.44, p\\u2009=\\u20090.025) \\nin the resistant group. Univariate analysis identified let-7b-5p (OR 3.17, \\n95%CI: 1.19-11.4, p\\u2009=\\u20090.04) and miR-27b-3p (OR 4.73, 95%CI: 1.4-26.6, p\\u2009=\\u20090.036) \\nas risk factors for resistance. The final multivariate model included miR-27b-3p \\n(OR 23.1, 95% CI: 2.8-452, p\\u2009=\\u20090.015), let-7b-5p (OR 4.38, 95% CI: 1.28-22.2, \\np\\u2009=\\u20090.038), and miR-103a-3p (OR 15.3, 95% CI: 1.33-351, p\\u2009=\\u20090.049). These miRNAs \\nmay serve as biomarkers of treatment response in MM. However, external \\nvalidation is necessary to confirm the clinical utility of our model.',\n",
       "  1: 'G protein-coupled estrogen receptor 1 (GPER1) activation is emerging as a \\npromising therapeutic strategy against several cancer types. While GPER \\ntargeting has been widely studied in the context of solid tumors, its effect on \\nhematological malignancies remains to be fully understood. Here, we show that \\nGPER1 mRNA is down-regulated in plasma cells from overt multiple myeloma (MM) \\nand plasma cell leukemia patients as compared to normal donors or pre-malignant \\nconditions (monoclonal gammopathy of undetermined significance and smoldering \\nMM); moreover, lower GPER1 expression associates with worse overall survival of \\nMM patients. Using the clinically applicable GPER1-selective agonist G-1, we \\ndemonstrate that the pharmacological activation of GPER1 triggered in vitro \\nanti-MM activity through apoptosis induction, also overcoming the protective \\neffects exerted by bone marrow stromal cells. Noteworthy, G-1 treatment reduced \\nin vivo MM growth in two distinct xenograft models, even bearing \\nbortezomib-resistant MM cells. Mechanistically, G-1 upregulated the miR-29b \\noncosuppressive network, blunting an established miR-29b-Sp1 feedback loop \\noperative in MM cells. Overall, this study highlights the druggability of GPER1 \\nin MM, providing the first preclinical framework for further development of \\nGPER1 agonists to treat this malignancy.',\n",
       "  2: 'Bone marrow stromal cell (BMSC)-derived small extracellular vesicles (sEVs) \\npromote drug resistance to bortezomib in multiple myeloma (MM) cells. \\nElucidating the components of BMSC sEV that induce drug resistance in MM cells \\ncould help identify strategies to overcome resistance. Considering the hypoxic \\nnature of the myeloma microenvironment, we explored the role of hypoxia in \\nregulating BMSC sEV cargo and investigated whether hypoxia-driven sEV miRNAs \\ncontribute to the drug resistance in MM cells. Hypoxia increased the release of \\nsEVs from BMSCs, and these sEVs more strongly attenuated bortezomib sensitivity \\nin MM cells than sEVs from BMSCs under normoxic conditions. RNA sequencing \\nrevealed that significantly elevated levels of miR-140-5p and miR-28-3p were \\nenclosed in hypoxic BMSCs-derived sEVs. Both miR-140-5p and miR-28-3p conferred \\nbortezomib resistance in MM cells by synergistically targeting SPRED1, a member \\nof the Sprouty protein family that regulates MAPK activation. SPRED1 inhibition \\nreduced sensitivity to bortezomib in MM cells through activating MAPK-related \\npathways and significantly promoted MM bortezomib resistance and tumor growth in \\na mouse model. These findings shed light on the role of hypoxia-induced miRNAs \\nshuttled in BMSC-derived sEVs to MM cells in inducing drug resistance and \\nidentify the miR-140-5p/miR-28-3p/SPRED1/MAPK pathway as a potential targetable \\naxis for treating MM.',\n",
       "  3: 'The miR-200b/429 located at 1p36 is a highly conserved miRNA cluster emerging as \\na critical regulator of cervical cancer. Using publicly available miRNA \\nexpression data from TCGA and GEO followed by independent validation, we aimed \\nto identify the association between miR-200b/429 expression and cervical cancer. \\nmiR-200b/429 cluster was significantly overexpressed in cancer samples compared \\nto normal samples. miR-200b/429 expression did not correlate with patient \\nsurvival; however, its overexpression correlated with histological type. \\nProtein-protein interaction analysis of 90 target genes of miR-200b/429 \\nidentified EZH2, FLT1, IGF2, IRS1, JUN, KDR, SOX2, MYB, ZEB1, and TIMP2 as the \\ntop ten hub genes.\\xa0PI3K-AKT and MAPK signaling pathways emerged as major target \\npathways of\\xa0miR-200b/429 and their hub genes. Kaplan-Meier survival analysis \\nshowed the expression of seven miR-200b/429\\xa0target genes (EZH2, FLT1, IGF2, \\nIRS1, JUN, SOX2, and TIMP2) to influence the overall survival of patients. The \\nmiR-200a-3p and miR-200b-5p could help predict cervical cancer with metastatic \\npotential. The cancer hallmark enrichment analysis showed hub genes\\xa0to promote \\ngrowth, sustained proliferation, resistance to apoptosis, induction of \\nangiogenesis, activation of invasion, and metastasis, enabling replicative \\nimmortality, evading immune destruction, and tumor-promoting inflammation. The \\ndrug-gene interaction analysis identified 182 potential drugs to interact with \\n27 target genes of miR-200b/429 with paclitaxel, doxorubicin, dabrafenib, \\nbortezomib, docetaxel, ABT-199, eribulin, vorinostat, etoposide, and \\nmitoxantrone emerging as\\xa0the top ten best candidate drugs. Taken together, \\nmiR-200b/429 and associated hub genes can be helpful for prognostic application \\nand clinical management of cervical cancer.',\n",
       "  4: 'The microRNAs (miRNAs), an extensive class of small noncoding RNAs (∼22 \\nnucleotides), have been shown to have critical functions in various biological \\nprocesses during development. miR-33b (or hsa-miR-33b) is down-regulated in \\ncancer of multiple systems. Notably, at least 27 protein-coding genes can be \\ntargeted by miR-33b. miR-33b regulates the cell cycle, cell proliferation, \\nvarious metabolism pathways, epithelial-mesenchymal transition (EMT), cancer \\ncell invasion and migration, etc. In prostate cancer, Cullin 4B (CUL4B) can be \\nrecruited to the promoter to inhibit the expression of miR-33b. In gastric \\ncancer, the hypermethylation of the CpG island regulated the expression of \\nmiR-33b. Besides, miR-33b could be negatively regulated by 7 \\ncompeting-endogenous RNAs (ceRNAs), which are all long non-coding RNAs \\n(lncRNAs). There are at least 4 signaling pathways, including NF-κB, MAP8, \\nNotch1, and Wnt/β-catenin signaling pathways, which could be regulated partially \\nby miR-33b. Additionally, low expression of miR-33b was associated with \\nclinicopathology and prognosis in cancer patients. In addition, the aberrant \\nexpression of miR-33b was connected with the resistance of cancer cells to 5 \\nanticancer drugs (cisplatin, docetaxel, bortezomib, paclitaxel, and \\ndaunorubicin). Importantly, our work systematically summarizes the aberrant \\nexpression of miR-33b in various neoplastic diseases and the effect of its \\ndownregulation on the biological behavior of cancer cells. Furthermore, this \\nreview focuses on recent advances in understanding the molecular regulation \\nmechanisms of miR-33b. Moreso, the relationship between the miR-33b expression \\nlevels and the clinicopathological data and prognosis of tumor patients was \\nsummarized for the first time. Overall, we suggest that the current studies of \\nmiR-33b are insufficient but provide potential hints and direction for future \\nmiR-33b-related research.',\n",
       "  5: 'Multiple myeloma is a hematological cancer type. For its treatment, Bortezomib \\nhas been widely used. However, drug resistance to this effective \\nchemotherapeutic has been developed for various reasons. 2D cell cultures and \\nanimal models have failed to understand the MM disease and Bortezomib \\nresistance. It is therefore essential to utilize new technologies to reveal a \\ncomplete molecular profile of the disease. In this review, we in-depth examined \\nthe possible molecular mechanisms that cause Bortezomib resistance and \\nspecifically addressed MM and Bortezomib resistance. Moreover, we also included \\nthe use of nanoparticles, 3D culture methods, microfluidics, and organ-on-chip \\ndevices in multiple myeloma. We also discussed whether the emerging technology \\noffers the necessary tools to understand and prevent Bortezomib resistance in \\nmultiple myeloma. Despite the ongoing research activities on MM, the related \\nstudies cannot provide a complete summary of MM. Nanoparticle and 3D culturing \\nhave been frequently used to understand MM disease and Bortezomib resistance. \\nHowever, the number of microfluidic devices for this application is \\ninsufficient. By combining siRNA/miRNA technologies with microfluidic devices, a \\ncomplete molecular genetic profile of MM disease could be revealed. Microfluidic \\nchips should be used clinically in personal therapy and point-of-care \\napplications. At least with Bortezomib microneedles, it could be ensured that MM \\npatients can go through the treatment process more painlessly. This way, MM can \\nbe switched to the curable cancer type list, and Bortezomib can be targeted for \\nits treatment with fewer side effects.',\n",
       "  6: 'BACKGROUND: Bortezomib resistance hampers the long-term survival of multiple \\nmyeloma (MM) patients. Our previous study has proved that downregulated lncRNA \\nMEG3 is associated with the poor clinical outcome in MM. However, the effect of \\nMEG3 on the sensitivity of bortezomib in MM and its possible molecular mechanism \\nremains muddled.\\nMETHODS: In this study, CCK8 and flow cytometry techniques were used to assess \\ncell viability in MEG3 overexpressed MM cells after bortezomib treatment. The \\nexpression of autophagy-related protein LC3 and p62 were distinguished by \\nWestern blot, and the mCherry-GFP-LC3 puncta reflecting autophagy level was \\nobserved under fluorescence microscope. RNA immunoprecipitation (RIP) technology \\nwas used to detect the binding relationship of MEG3 and ATG2B to PTBP1.\\nRESULTS: Increased toxicity of bortezomib and diminished autophagy level were \\nfound in MEG3 overexpressed MM cells. Mechanistically, we discovered that \\nRNA-binding protein PTBP1 could bind to MEG3 and ATG2B by RIP assay. \\nUpregulation of MEG3 promoted PTBP1 expression and inhibited the expression \\nlevel of ATG2B, suggesting that MEG3 recruited PTBP1 and then decayed ATG2B \\nexpression.\\nCONCLUSION: In summary, our study illustrated that MEG3 increased bortezomib \\nsensitivity by hindering autophagy through the PTBP1/ATG2B axis, providing a new \\ntherapeutic target for bortezomib-resistant MM patients.',\n",
       "  7: \"Circular RNAs (circRNAs) have been shown to play critical regulatory roles in \\nmultiple myeloma progression. Here, we aimed to explore the biologic role of \\ncirc_0005615 in multiple myeloma progression and its associated mechanism. Cell \\ncounting kit-8 assay was conducted to analyze the bortezomib resistance and \\nproliferation of multiple myeloma cells. Cell proliferation was also analyzed by \\n5-Ethynyl-2'-deoxyuridine incorporation and flow cytometry assays. Cell \\napoptosis was assessed by flow cytometry. The interaction between \\nmicroRNA-185-5p (miR-185-5p) and circ_0005615 or interferon regulatory factor 4 \\n(IRF4) was verified by the dual-luciferase reporter and RNA immunoprecipitation \\n(RIP) assays. A xenograft tumor model was established in non-obese \\ndiabetic/server combined immune-deficiency mice to analyze the roles of \\ncirc_0005615 in tumor growth and bortezomib resistance. Circ_0005615 was \\nupregulated in multiple myeloma tissues and cell lines. Circ_0005615 knockdown \\nrestrained the bortezomib resistance and proliferation and induced the apoptosis \\nof multiple myeloma cells. Circ_0005615 acted as a molecular sponge for \\nmiR-185-5p, and the antitumor effects mediated by circ_0005615 knockdown were \\nreversed by silencing miR-185-5p. IRF4 was confirmed as a direct target of \\nmiR-185-5p, and miR-185-5p overexpression-induced antitumor influences could be \\ncounteracted by IRF4 overexpression. Circ_0005615 could positively regulate IRF4 \\nexpression by sponging miR-185-5p in multiple myeloma cells. Circ_0005615 \\nknockdown suppressed the growth and bortezomib resistance of xenograft tumors in \\nvivo. Circ_0005615 contributed to the malignant progression and bortezomib \\nresistance of multiple myeloma through mediating miR-185-5p/IRF4 signaling.\",\n",
       "  8: 'OBJECTIVE: Long non-coding RNA ANGPTL1-3 (lnc-ANGPTL1-3) is previously observed \\nto induce bortezomib resistance via targeting microRNA-30a (miR-30a) in multiple \\nmyeloma (MM). Hence, this study aimed to further explore the relationship \\nbetween lnc-ANGPTL1-3 and miR-30a and their linkage with disease properties and \\nprognosis in bortezomib-treated MM patients.\\nMETHODS: Fifty-nine MM patients underwent treatment with the bortezomib-based \\nregimen, and 30 healthy donors were consecutively enrolled. Bone marrow samples \\nwere collected from MM patients (before therapy) and healthy donors; then, \\nplasma cells were separated for lnc-ANGPTL1-3 and miR-30a detection by RT-qPCR. \\nThen treatment response, progression-free survival (PFS), and overall survival \\n(OS) of MM patients were assessed.\\nRESULTS: Lnc-ANGPTL1-3 was upregulated while miR-30a was downregulated in MM \\npatients compared to healthy donors (both P\\u2009<\\u20090.001), then a negative \\ncorrelation between lnc-ANGPTL1-3 and miR-30a was found in MM patients \\n(P\\u2009<\\u20090.001) instead of in health donors (P\\u2009=\\u20090.188). In MM patients, \\nlnc-ANGPTL1-3 correlated with increased t (4;14) (P\\u2009=\\u20090.033), Del (17p) \\n(P\\u2009=\\u20090.018), ISS stage (P\\u2009=\\u20090.020), R-ISS stage (P\\u2009=\\u20090.025) but not t (14;16) \\n(P\\u2009=\\u20090.255) or Durie-Salmon stage (P\\u2009=\\u20090.186); while miR-30a only related to \\ndecreased t (14;16) (P\\u2009=\\u20090.025) and R-ISS stage (P\\u2009=\\u20090.006). Besides, \\nlnc-ANGPTL1-3 predicted lower complete response (CR) (P\\u2009=\\u20090.034), poor PFS \\n(P\\u2009=\\u20090.016) and OS (P\\u2009=\\u20090.041) but not objective response rate (ORR) \\n(P\\u2009=\\u20090.128). However, miR-30a forecasted higher CR (P\\u2009=\\u20090.013), prolonged PFS \\n(P\\u2009=\\u20090.014), and OS (P\\u2009=\\u20090.045) but not ORR (P\\u2009=\\u20090.407).\\nCONCLUSION: Lnc-ANGPTL1-3 negative correlates with miR-30a, which links with key \\ncytogenetic features, ISS/R-ISS stage, and prognosis in MM patients who \\nunderwent treatment of bortezomib-based regimen.',\n",
       "  9: 'Circular RNAs (circRNAs) are a novel type of covalently closed RNAs involved in \\nseveral physiological and pathological processes. They display tissue-specific \\nexpression and are constant, abundant, and highly conserved, making them perfect \\nmarkers for diagnosis and prognosis. Several studies have proposed that circRNAs \\nare also differentially produced in malignancies where they have oncogenic \\neffects. Furthermore, circRNAs affecting microRNAs modify the expression profile \\nof several transcription factors which play essential roles in tumors. CircRNAs \\nwithin the hematopoietic compartment were identified as modulators of mechanisms \\nable to enhance or suppress tumor progression in blood malignancies. Moreover, \\nseveral circRNAs were suggested to confer resistance to the conventional drugs \\nemployed in hematopoietic cancers. In this review, we highlight the growing role \\nand the controlling mechanisms by which circRNAs modify multiple myeloma \\ngenesis. We propose that circRNAs can be considered as potential diagnostic and \\nprognostic markers, can induce chemoresistance, and might represent novel \\ntherapeutic targets for multiple myeloma.',\n",
       "  10: 'OBJECTIVE: This study investigated the mechanism by which miR-197-3p regulated \\nIL-6 expression and reduced bortezomib (BTZ) resistance in multiple myeloma \\n(MM).\\nMETHODS: The expression of miR-197-3p, MEAF6 and IL-6 in BTZ-resistant MM cells \\nwas measured. The effects of miR-197-3p/IL-6 axis on drug resistance and cell \\napoptosis were evaluated in BTZ-resistant MM cells. The expression of JAK/STAT3 \\nproteins was detected by Western blotting. The binding of miR-197-3p to MEAF6 \\nmRNA was verified using molecular biology techniques. Chromatin \\nimmunoprecipitation was used to assess histone acetylation in IL-6 promoter. The \\neffect of miR-197-3p on MM growth was investigated in a mouse model.\\nRESULTS: MiR-197-3p was lowly expressed, and MEAF6 and IL-6 were highly \\nexpressed in BTZ-resistant MM cells. Overexpression of miR-197-3p increased drug \\nsensitivity in BTZ-resistant MM cells, which was counteracted by overexpression \\nof IL-6. Overexpression of miR-197-3p also inhibited MM growth in vivo. \\nMechanistically, miR-197-3p suppressed the expression of IL-6 by inhibiting \\nMEAF6-mediated histone H3 acetylation in IL-6 promoter. The miR-197-3p/IL-6 axis \\nalso inhibited the activation of JAK/STAT3 signaling pathway.\\nCONCLUSION: miR-197-3p reduces BTZ resistance in MM by inhibiting \\nacetylation-mediated expression of IL-6 and by inactivating JAK/STAT3 signaling \\npathway.',\n",
       "  11: 'INTRODUCTION: Changes in microRNAs (miRs) contribute to the alternative \\nchemo-resistance of cancers. Bortezomib (BTZ) is a well-characterized anticancer \\nagent that inhibits proteasome, and its effect is associated with the function \\nof miRs. Based on the data of microarray assay and comprehensive bioinformatics \\nanalyses, in the current study, we explored the role of miR-466 and its \\ndownstream effector CCND1 in the BTZ-resistance of non-small-cell lung cancer \\n(NSCLC) cells.\\nMETHODS: miR expression profiles in NSCLC tissues and paratumor tissues were \\ndetermined with microarray assay. The potential miR involved in the \\nchemo-resistance of NSCLC cells was explored via a series of bioinformatics \\nanalyses, and miR-466 was selected. Afterward, levels of miR-466 and CCND1 were \\ninvestigated in NSCLC samples and analyzed by clinicopathologic parameters, \\nincluding age, sex, stage of NSCLC, tumor size, tumor differentiation status, \\nand lymphocytic infiltration status. The expression of CCND1 and miR-466 was \\nthen modulated in vitro to explore the influence on cell phenotypes, which was \\nthen verified with mouse models.\\nRESULTS: Based on microarray detection, 287 miRs were dysexpressed between NSCLC \\ntissues and paratumor tissues, including 90 upregulated members and 197 \\ndownregulated members. After bioinformatics analyses and reverse transcription \\nquantitative PCR validation, miR-466 and CCND1 were selected. Following clinical \\ninvestigations, miR-466 was downregulated, while CCND1 was upregulated in NSCLC \\nsamples, contributing to the advanced cancer progression. The overexpression of \\nCCND1 increased cell viability, suppressed cell apoptosis, decreased p21 and \\ninduced N-cadherin, CCND2, and CDK4 under BTZ treatment. The induced expression \\nof miR-466 re-sensitized NSCLC cells to BTZ treatment. In the animal model, the \\noverexpression of CCND1 impaired the inhibitory effect of BTZ on the growth and \\nmetastasis of solid tumor, which was restored by miR-466 induction.\\nCONCLUSION: The findings showed that the interaction between BTZ, miR-466, and \\nCCND1 determined the antitumor effect of BTZ on NSCLC.',\n",
       "  12: 'Multiple myeloma (MM) progression and drug resistance depend on the crosstalk \\nbetween MM cells and bone marrow (BM) fibroblasts (FBs). During monoclonal \\ngammopathy of undetermined significance (MGUS) to MM transition, MM cell-derived \\nexosomes (EXOs) reprogram the miRNA (miR) profile of FBs, inducing the \\noverexpression miR-23b-3p, miR-27b-3p, miR-125b-5p, miR-214-3p, and miR-5100. \\nHere, we demonstrate that the miR content of MM FB-derived EXOs (FB-EXOs) \\noverlaps the miR profile of parental FBs by overexpressing comparable levels of \\nmiR-23b-3p, miR-27b-3p, miR-125b-5p, miR-214-3p, and miR-5100. Recipient MM \\ncells co-cultured with MM FB-EXOs selectively overexpress only miR-214-3p and \\nmiR-5100 but not miR-23b-3p, miR-27b-3p, and miR-125b-5p, suggesting a putative \\nselective transfer. MM cells express HOTAIR, TOB1-AS1, and MALAT1 lncRNAs. \\nTransient transfection of MM cells with lnc·siRNAs demonstrates that HOTAIR, \\nTOB1-AS1, and MALAT1 lncRNAs are sponges for miR-23b-3p, miR-27b-3p, and \\nmiR-125b-5p. Indeed, lncRNA knockdown significantly increased miR levels in \\nU266\\u2009MM cells co-cultured with MM FB-EXOs. Selective miR-214-3p and miR-5100 \\noverexpression modulates MAPK, PI3K/AKT/mTOR, and p53 pathways in MM cells. \\nInterrogation using the DIANA tools algorithm and transient overexpression using \\nmiR mimic probes confirmed the involvement of miR-214-3p and miR-5100 and their \\ntarget genes, PTEN and DUSP16, respectively, in the modulation of these \\nintracellular pathways. Finally, the uptake of EXOs as well as miR-214-3p and \\nmiR-5100 overexpression increase MM cell proliferation and resistance to \\nbortezomib-induced apoptosis by switching the balance between \\npro-/anti-apoptotic proteins. Overall, these data show that MM cells are not \\nsimply a container into which EXOs empty their cargo. On the contrary, tumour \\ncells finely neutralize exosomal miRs via lncRNA expression to ensure their \\nsurvival. © 2021 The Pathological Society of Great Britain and Ireland.',\n",
       "  13: 'Multiple myeloma (MM) is a malignant cancer with an increasing in incidence that \\ncan be alleviated through bortezomib (BTZ) treatment. Activating transcription \\nfactor 3 (ATF3) plays a major role in cancer development. Moreover, microRNAs \\n(miRNAs) regulate carcinogenic pathways, apoptosis, and programmed necrotic cell \\ndeath. However, the detailed mechanism by which ATF3 modulates BTZ drug \\nsensitivity/resistance remains elusive. In the current study, expression of ATF3 \\nwas significantly increased under BTZ treatment in a dose-dependent manner in MM \\ncell lines. In addition, ATF3 could regulate cell apoptosis under BTZ treatment. \\nThe effect of ATF3 was negatively regulated by its binding miRNA, miR-135a-5p. \\nWhen either ATF3 was silenced or miR-135a-5p mimics were added to MM cells, they \\npartially lost sensitivity to BTZ treatment. This was accompanied by low levels \\nof Noxa, CHOP, and DR5, and a decrease in mitochondrial membrane potential. \\nThese results revealed the combinatorial regulatory patterns of ATF3 and \\nmiR-135a-5p in the regulatory protein interactome, which indicated a clinical \\nsignificance of the miR-135a-5p-ATF3 protein interaction network in BTZ therapy. \\nThis study provides potential evidence for further investigation into BTZ \\nresistance.',\n",
       "  14: \"Multiple myeloma is a frequent hematologic malignancy. Bortezomib is the \\nfirst-line drug for multiple myeloma chemotherapy. The present study aimed to \\ninvestigate the potential role and mechanism of circular RNA chaperonin \\ncontaining TCP1 subunit 3 (circ-CCT3) in bortezomib resistance of multiple \\nmyeloma. The levels of circ-CCT3, microRNA-223-3p (miR-223-3p), and \\nbromodomain-containing 4 (BRD4) were detected by quantitative real-time PCR or \\nwestern blot. Cell Counting Kit-8 (CCK-8) method was used to measure the \\nhalf-inhibitory concentration of bortezomib and cell viability. Cell cycle \\ndistribution, apoptosis, proliferation and migration were determined by flow \\ncytometry, 5-ethynyl-2'-deoxyuridine, and wound healing assay. The levels of \\nrelevant proteins were checked via western blot. The binding association between \\nmiR-223-3p and circ-CCT3/BRD4 was validated via a dual-luciferase reporter \\nassay. Circ-CCT3 and BRD4 were upregulated, while miR-223-3p was downregulated \\nin bortezomib-resistant multiple myeloma patients and cells. Silencing of \\ncirc-CCT3 enhanced the sensitivity of bortezomib-resistant multiple myeloma \\ncells to bortezomib. Circ-CCT3 knockdown weakened bortezomib resistance via \\nmodulating miR-223-3p. Moreover, miR-223-3p increased bortezomib sensitivity by \\ninhibiting BRD4. Downregulation of circ-CCT3 attenuated bortezomib resistance of \\nmultiple myeloma via regulating miR-223-3p/BRD4 pathway, which provided a new \\npotential target for multiple myeloma chemoresistance.\",\n",
       "  15: 'Multiple myeloma (MM) is a common malignant hematological malignancy. Recently, \\ninterest has grown in the role of non-coding regions in disease pathogenesis. \\nMicroRNAs (miRNAs) are small non-coding RNAs containing 19-25 bases that play a \\ncrucial role in messenger RNA silencing and post-transcriptional regulation of \\ngene expression. Several miRNAs demonstrate markedly dysregulated expression in \\nMM, suggesting that they may act as both tumor suppressors and oncogenes. \\nmicroRNAs are also reportedly involved in the regulation of other epigenetic \\nmechanisms of gene expression. Additionally, some miRNAs have been associated \\nwith drug resistance, and therefore a further exploration of their activity may \\nlead to its reversal. Moreover, miRNA expression patterns in either MM cells or \\nserum exosomes have been shown to be good prognostic markers. This review \\ndescribes the roles of miRNAs in MM and examines their potential to predict MM \\nprognosis and play a role in novel therapeutic strategies.',\n",
       "  16: \"INTRODUCTION: Multiple myeloma (MM) remains an incurable disease, and patient \\nsurvival requires a better understanding of this malignancy's molecular aspects. \\nHeparanase (HPSE) is highly expressed in aggressive MM cells and related to \\ntumor growth, metastasis, and bortezomib (BTZ) resistance. Thus, targeting HPSE \\nseems to be a promising approach for MM treatment, and because microRNAs \\n(miRNAs) have emerged as potential regulators of HPSE expression, the use of \\nextracellular vesicles (EVs) can allow the efficient delivery of therapeutic \\nmiRNAs.\\nMETHODS: We used prediction algorithms to identify potential miRNAs that \\nregulate negatively HPSE expression. RT-qPCR was performed to assess miRNAs and \\nHPSE expression in MM lines (U266 and RPMI-8226). Synthetic miRNA mimics were \\nelectroporated in MM cells to understand the miRNA contribution in HPSE \\nexpression, glycosaminoglycans (GAGs) profile, cell proliferation, and cell \\ndeath induced by BTZ. EVs derived from HEK293T cells were engineered with miRNAs \\nto evaluate their therapeutic potential combined with BTZ.\\nRESULTS: It revealed a direct association between BTZ sensitivity, HPSE, and \\nmiR-1252-5p expressions. Moreover, overexpression of miR-1252-5p significantly \\nreduced HPSE expression and HPSE enzymatic activity in MM cells. The higher \\nlevel of miR-1252-5p was correlated with a reduction of cell viability and \\nhigher sensitivity to BTZ. Further, EVs carrying miR-1252-5p increased MM cells' \\nsensitivity to BTZ treatment.\\nCONCLUSION: These results showed that miR-1252-5p could negatively regulate HPSE \\nin MM, indicating the use of EVs carrying miR-1252-5p as a potential novel BTZ \\nsensitization approach in MM cells.\",\n",
       "  17: 'Multiple myeloma (MM) is a malignant neoplasm featured by obvious drug \\nresistance and poor prognosis. MicroRNAs (miRNAs) are a class of small noncoding \\nRNAs with crucial roles in many biological processes including cancer initiation \\nand progression. The current study aims to investigate the pathogenic role and \\nmolecular mechanism of miRNAs in MM drug resistance. In the present study, The \\nexpression profile of miRNAs in MM samples was analyzed by microarray and \\nreal-time polymerase chain reaction. Protein expressions were detected by \\nWestern blot analysis. Cell apoptosis was detected by the Annexin V staining \\nassay. The interaction between miRNA and the targeting mRNA was assessed using \\nDual luciferase reporter assay. Herein, we show that expression profile of \\nmiRNAs is deregulated in MM. miR-218, one of the most aberrational miRNAs in MM, \\nis significantly decreased in MM cells compared to peripheral blood mononuclear \\ncell (PBMC). Genetic manipulation reveals miR-218 control the response of MM \\ncells to anticancer drug bortezomib (BTZ). Overexpression of miR-218 causes a \\nsignificant aberrant genes expression including leucine rich repeat containing \\n28 (LRRC28). Mechanistic study shows that miR-218 control the drug response \\nthrough mediating the expression of LRRC28 in MM cells. Overexpression of LRRC28 \\nsignificantly reserves miR-218-mediated cell response to BTZ. Taken together, \\nmiR-218 is decreased in MM that contributes to BTZ resistance via targeting \\nLRRC28, which might be used as a novel therapeutic target for multiple myeloma.',\n",
       "  18: \"The bone marrow microenvironment plays an essential role in multiple myeloma \\n(MM) progression. We aimed to explore the alterations of levels of long \\nnoncoding RNAs and messenger RNAs (mRNAs), derived from exosomes in peripheral \\nblood, in resistance to bortezomib (Btz) of MM patients. Peripheral blood \\nsamples were collected from five Btz-resistant and five Btz-sensitive MM \\npatients. Exosomes in patients' peripheral blood were enriched, and the profiles \\nof long noncoding RNAs (lncRNAs) and mRNAs in exosomes were determined using \\ndeep sequencing. Bioinformatics analysis was performed to explore biological \\nfunction. MTS was employed to determine the viability of Roswell Park Memorial \\nInstitute (RPMI) 8226 and LP-1 cells incubated with exosomes derived from \\nBtz-resistant patients. Quantitative polymerase chain reaction (qPCR) was used \\nto evaluate the levels of exosomal FFAR1, SP9, HIST1H2BG, and ITIH2. Incubation \\nwith Btz-resistant patient-derived exosomes significantly increased the \\nviability of Btz-treated RPMI 8226 and LP-1 cells in a dose-dependent manner. We \\nidentified 482 lncRNAs and 2099 mRNAs deregulated in exosomes of the \\nBtz-resistance group; and 78 mRNAs were enriched in DR-related pathways, \\nincluding mammalian target of rapamycin, platinum drug resistance, and the cAMP \\nand phosphoinositide 3-kinase-Akt signaling pathways. qPCR results verified the \\nincreases in FFAR1 and SP9 and decreases in HIST1H2BG and ITIH2 in Btz-resistant \\npatient-derived exosomes. Moreover, exosomal FFAR1 and SP9 exhibited potential \\nas independent prognostic indicators of survival of MM patients. Our study \\nreveals significant dysregulation of exosomal RNA components in the \\nBtz-resistant group of MM patients as well as several mRNAs that may be used as \\nbiomarkers of prognosis of MM patients that are resistant to Btz.\",\n",
       "  19: \"The mechanisms of drug resistance in multiple myeloma are poorly understood. \\nHere we show that CD47, an integrin-associated receptor, is significantly \\nupregulated in drug resistant myeloma cells in comparison with parental cells, \\nand that high expression of CD47 detected by immunohistochemistry is associated \\nwith shorter progression free and overall survivals in multiple myeloma \\npatients. We show that miR-155 is expressed at low levels in drug resistant \\nmyeloma cells and is a direct regulator of CD47 through its 3'UTR. Furthermore, \\nlow miR-155 levels are associated with advanced stages of disease. MiR-155 \\noverexpression suppressed CD47 expression on myeloma cell surface, leading to \\ninduction of phagocytosis of myeloma cells by macrophages and inhibition of \\ntumor growth. MiR-155 overexpression also re-sensitized drug-resistant myeloma \\ncells to bortezomib leading to cell death through targeting TNFAIP8, a negative \\nmediator of apoptosis in vitro and in vivo. Thus, miR-155 mimics may serve as a \\npromising new therapeutic modality by promoting phagocytosis and inducing \\napoptosis in patients with refractory/relapsed multiple myeloma.\",\n",
       "  20: 'The overall survival of multiple myeloma (MM) patients significantly improved \\nwith the use of proteasome inhibitor such as bortezomib. However, resistance to \\nsorafenib limits its use. Bortezomib-resistant MM cells were generated and their \\nbortezomib-resistant properties were confirmed by cell viability and apoptosis \\nassays. To explore functions and underlying mechanisms of long non-coding RNA \\nnuclear paraspeckle assembly transcript 1 (NEAT1) on bortezomib resistance in \\nMM, MTT assays, ﬂow cytometry analyses, dual luciferase report gene assays, RNA \\npulldown assays and chromatin immunoprecipitation assays were carried out. NEAT1 \\nand specific protein 1 (Sp1) was upregulated while miR-29b-3p was down regulated \\nin bortezomib-resistant MM cells. NEAT1 promoted Sp1 expression by sponging \\nmiR-29b-3p and then enhanced the tolerance of MM cells to bortezomib. Sp1 \\ntargeted to NEAT1 promoter region promoting NEAT1 transcription and formed a \\npositive feedback loop. NEAT1 and Sp1 levels were higher and miR-29b-3p was \\nlevels were lower in bortezomib-resistant MM patients. NEAT1/miR-29b-3p/Sp1 \\nfeedback loop enhanced the tolerance of MM cells to bortezomib. These results \\nindicate potentially valuable targets for overcoming bortezomib resistance for \\nMM.',\n",
       "  21: 'Circular RNAs (circRNAs) possess important regulatory effects on multiple \\nmyeloma (MM) progression. Here, we aimed at exploring the function of \\ncirc_0007841 in MM and the underlying molecular mechanism. Expression of \\ncirc_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via \\nqRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was \\napplied to examine cell viability and IC50 value of MM cells to bortezomib \\n(BTZ). Colony formation assay was performed to analyze cell proliferation. \\nMoreover, cell apoptosis was assessed by flow cytometry and western blot \\nanalysis. Cell metastasis was evaluated by wound healing assay and Transwell \\nassay. Function of circ_0007841 in vivo was determined by xenograft tumor assay. \\nTarget relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed \\nvia dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down \\nassays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of \\nmiR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 \\nknockdown significantly repressed cell proliferation, chemoresistance, and \\nmetastasis, while contributed to apoptosis of MM cells in vitro, and reduced \\ntumor growth in vivo. Circ_0007841 targeted miR-129-5p, and miR-129-5p \\ninhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a \\nmRNA target of miR-129-5p, whose overexpression could undermine the \\nmiR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 \\nexpression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell \\nproliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 \\naxis, suggesting that circ_0007841 might serve as a potential therapeutic target \\nof MM.',\n",
       "  22: 'AIMS: Bortezomib (BTZ) is described as the first-line agent for multiple myeloma \\n(MM) chemotherapy, but the emergence of BTZ resistance usually results in the \\nfailure of chemotherapy in MM. Circular RNA (circRNA) itchy E3 ubiquitin protein \\nligase (circITCH) is a novel identified circRNA that plays a vital role in the \\ndevelopment of human cancers. However, the role of circITCH in the development \\nof BTZ resistance in MM remains elusive.\\nMATERIALS AND METHODS: The expression of circITCH, miR-615-3p, and protein \\nkinase C, delta (PRKCD) was detected with quantitative reverse transcription PCR \\nand western blot. The effects of circITCH on the sensitivity of MM cells to BTZ \\nwere assessed using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium \\nbromide assay, flow cytometry, and xenograft tumor assay. The interaction of \\ncircITCH, microRNA-615-3p, and PRKCD was explored using luciferase reporter \\nassay and RNA immunoprecipitation assay.\\nKEY FINDINGS: circITCH was downregulated in MM bone marrow specimens and cell \\nlines, as well as BTZ-resistant MM cells. Reduced expression of circITCH was \\nindicative of poor prognosis in MM patients. Upregulation of circITCH enhanced \\nthe sensitivity of BTZ-resistant MM cells to BTZ in vitro and in vivo. \\nFurthermore, circITCH was identified as a sponge for miR-615-3p, and PRKCD is \\nconfirmed as a direct target of miR-615-3p. Besides, circITCH overexpression \\nenhanced the sensitivity of MM cells to BTZ through miR-615-3p/PRKCD axis.\\nSIGNIFICANCE: circITCH overexpression enhanced the sensitivity of MM cells to \\nBTZ through miR-615-3p/PRKCD axis, providing a novel potential target for \\ncombating BTZ resistance in patients with MM.',\n",
       "  23: 'Bortezomib is the first-in-class proteasome inhibitor, commonly used in the \\ntreatment of multiple myeloma (MM). The mechanisms underlying acquired \\nbortezomib resistance in MM are poorly understood. Several cell-free miRNAs have \\nbeen found to be aberrantly regulated in MM patients. The aim of this pilot \\nstudy was to identify a blood-based miRNA signature that predicts \\nbortezomib-based therapy efficacy in MM patients. Thirty MM patients treated \\nwith bortezomib-based regimens were studied, including 19 with refractory \\ndisease and 11 who were bortezomib sensitive. Serum miRNA expression patterns \\nwere identified with miRCURY LNA miRNA miRNome PCR Panels I+II (Exiqon/Qiagen). \\nUnivariate analysis found a total of 21 miRNAs to be differentially expressed in \\npatients with MM according to bortezomib sensitivity. Multivariate logistic \\nregression was created and allowed us to discriminate refractory from sensitive \\npatients with a very high AUC of 0.95 (95%CI: 0.84-1.00); sensitivity, \\nspecificity and accuracy were estimated as 0.95, 0.91, and 0.93. The model used \\nexpression of 3 miRNAs: miR-215-5p, miR-181a-5p and miR-376c-3p. This study is \\nthe first to demonstrate that serum expression of several miRNAs differs between \\npatients who are bortezomib refractory and those who are sensitive which may \\nprove useful in studies aimed at overcoming drug resistance in MM treatment.',\n",
       "  24: 'BACKGROUND: It has been demonstrated that circular RNA (circRNA) plays a crucial \\nrole in the occurrence and development of tumors, but the diagnostic and \\npredictive value of most circRNAs in tumor patients remains unclear, especially \\nfor multiple myeloma (MM).\\nMETHODS: High-throughput circRNA microarray-based sequencing was used to \\nidentify the differentially expressed circRNAs in MM. qRT-PCR was then employed \\nto detect hsa_circRNA_101237 expression levels in the bone marrow tissues from \\n143 MM patients (65 first-episode treatment-naive patients and 78 patients with \\nrecurrent/refractory disease), MM cells and bortezomib-resistant MM cell lines. \\nWhether hsa_circRNA_101237 can be used as a potential biomarker and therapeutic \\ntarget for MM was investigated.\\nRESULTS: The average expressions of hsa_circRNA_101237 in the bone marrow \\ntissues from MM patients (especially those with recurrent/refractory disease), \\nMM cells and bortezomib-resistant MM cell lines were increased significantly \\n(P<0.01). hsa_circRNA_101237 was overexpressed in patients positive for 13q14 \\ndeletion, 1q21 amplification, P53 deletion, and t(4,14) and t(14,16). \\nhsa_circRNA_101237 was closely related to prognosis of the patients, and its \\nhigh expression was associated with shorter OS and PFS. In addition, those \\noverexpressing hsa_circRNA_101237 were less responsive to bortezomib treatment. \\nBioinformatic analysis indicated that hsa_circRNA_101237 interacted with 11 \\nmiRNAs and 10 candidate mRNAs. This finding may shed new light on the subsequent \\nstudies on the working mechanism and functions.\\nCONCLUSION: It was first reported that hsa_circRNA_101237 was significantly \\nupregulated in MM. It was indicated that hsa_circRNA_101237 may be a novel \\nbiomarker for MM, and it plays a significant role in the occurrence and \\ndevelopment of MM.',\n",
       "  25: 'Overexpression of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) is \\nimplicated in drug resistance and progression of multiple myeloma (MM). The \\nbasis for MARCKS induction and impact on MM are not known. Here we show that \\nmicroRNA-34a (miR-34a), regulates MARCKS translation and is under-expressed in \\ndrug-resistant MM cells, leading to increased MARCKS protein level. \\nOver-expression of miR-34a reduces MARCKS expression and sensitizes resistant \\ncells to anti-myeloma drugs. A MARCKS peptide inhibitor (MPS) exerts a dose \\ndependent cytotoxic effect on drug-resistant MM cells with minimal cytotoxicity \\nto normal hematopoietic cells. MPS synergizes with the proteasomal-inhibitor \\nbortezomib to effectively kill drug-resistant MM cells both in vitro and in a \\nxenograft model of MM. While MARCKS inhibition killed MM cells, it also enhanced \\na pro-survival autophagic pathway that sustained growth following MARCKS \\ninhibition. In accordance, combined treatment with MARCKS antagonists, \\nbortezomib and the autophagy inhibitor, chloroquine, significantly diminished \\ntumor growth in drug-resistant MM cell lines as well as primary MM cells. This \\nstudy uncovers a mechanism of drug resistance involving miR-34a-MARCKS \\nautoregulatory loop and provides a framework for a potentially new therapeutic \\nstrategy to overcome drug resistance in multiple myeloma.',\n",
       "  26: \"BACKGROUND: Multiple myeloma (MM) cells gain protection against drugs through \\ninteraction with bone marrow stromal cells (BMSCs). This form of resistance \\nlargely accounts for resistance to therapy in MM patients which warrants further \\nexploration to identify more potential therapeutic targets.\\nMETHODS: We performed miRNA/mRNA qPCR arrays and western blotting to analyze \\ntranscriptional and translational changes in MM cells co-cultured with BMSCs. \\nDrug cytotoxicity and apoptosis in MMGFP-BMSC co-cultures were measured using \\nfluorescence plate reader and flowcytometry, respectively. miRNA was \\noverexpressed in MM cell lines using Lentiviral transduction, miRNA-3'UTR \\nbinding was examined using luciferase assay.\\nRESULTS: We found that BMSCs downregulated miR-101-3p and upregulated survivin \\n(BIRC5) in MM cells. Survivin was downregulated by miR-101-3p overexpression and \\nfound to be a direct target of miR-101-3p using 3'UTR luciferase assay. \\nOverexpression of survivin increased viability of MM cells in the presence of \\nanti-myeloma drugs, and miR-101-3p inhibition by anti-miR against miR-101-3p \\nupregulated survivin. Furthermore, overexpression of miR-101-3p or silencing of \\nsurvivin triggered apoptosis in MM cells and sensitized them to anti-myeloma \\ndrugs in the presence of BMSCs overcoming the stroma-induced drug resistance.\\nCONCLUSIONS: Our study demonstrates that BMSC-induced resistance to drugs is \\nassociated with survivin upregulation which is a direct target of miR-101-3p. \\nThis study also identifies miR-101-3p-survivin interaction as a druggable target \\ninvolved in stroma-mediated drug resistance in MM and suggests it for developing \\nmore efficient therapeutic strategies.\",\n",
       "  27: \"Background: Nowadays, microRNAs (miRNAs) attract much attention in regulating \\nanticancer drug resistance in cancers including multiple myeloma (MM). \\nBortezomib is the first-line choice in MM treatment, and bortezomib resistance \\ncaused by aberrant DNA repair leads to the recurrence and therapeutic failure of \\nMM. Objective: Our study aims to identify a miRNA that overcomes bortezomib \\nresistance in MM. Methods: We established bortezomib-resistant MM cell lines, \\nand screened several miRNAs that have aberrant expressions in MM cell lines. The \\nexpression of DNA-repair-related proteins were assessed by western blot, and \\ncell viability was determined by the MTT assay in bortezomib-resistant cell \\nlines. The binding between miRNAs and 3'-UTR of APE1 mRNA was confirmed by \\nluciferase reporter assay. The mouse bortezomib-resistant xenograft was \\nestablished to verify the therapeutic effect of miRNA overexpression. Results: \\nmiR-520g and miR-520h were significantly downregulated in bortezomib-resistant \\nMM cell lines, and overexpression of miR-520g and miR-520h together inhibited \\nexpression of homologous recombination-related protein Rad51 and cell viability \\nof bortezomib-resistant MM cells in vitro by binding with 3'-UTR of APE1 mRNA. \\nCombined overexpression of miR-520g and miR-520h inhibited bortezomib-resistant \\nMM tumor growth in vivo. Conclusion: Our findings demonstrated that combined \\noverexpression of miR-520g and miR-520h overcomes bortezomib resistance in MM \\nthrough inhibition of DNA repair, offering a promising therapeutic target for MM \\ntreatment.\",\n",
       "  28: 'Multiple Myeloma (MM) is a malignant hematological disease characterized by \\nmonoclonal proliferation of plasma cells in the bone marrow. In recent years, \\nthe widespread use of new drugs based on bortezomib (Btz) has significantly \\nimproved the remission rate of MM patients. However, drug resistance and disease \\nrelapse occur within a few years and MM is still considered to be an incurable \\ndisease. The amplification of the long arm of chromosome 1 is one of the most \\ncommon genetic abnormalities in MM patients. Here, we found that long non-coding \\nRNA ANGPTL1-3 which located in 1q region was overexpressed in MM. Lnc-ANGPTL1-3 \\nexpression was correlated with MM International Staging System (ISS) and overall \\nsurvival. Notably, knockdown of lnc-ANGPTL1-3 increased Btz sensitivity of MM \\ncells. Following exploration revealed that lnc-ANGPTL1-3 competitively \\ninteracted with miR-30a-3p to c-Maf, a transcription factor which was reported \\nto be associated with Btz resistance. Taken together, our findings demonstrate \\nthat lnc-ANGPTL1-3/miR-30a-3p/c-Maf axis plays a critical role in MM Btz \\nresistance.',\n",
       "  29: 'MicroRNAs (miRNAs) regulate gene expression post-transcriptionally. In this way \\nthey might influence whether a cell is sensitive or resistant to a certain drug. \\nSo far, only a limited number of relatively small scale studies comprising few \\ncell lines and/or drugs have been performed. To obtain a broader view on miRNAs \\nand their association with drug response, we investigated the expression levels \\nof 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. \\nFor this purpose IC50 values of a drug screen involving 34 drugs were associated \\nwith miRNA expression data of the same breast cancer cell lines. Since molecular \\nsubtype of the breast cancer cell lines is considered a confounding factor in \\ndrug association studies, multivariate analysis taking subtype into account was \\nperformed on significant miRNA-drug associations which retained 13 associations. \\nThese associations consisted of 11 different miRNAs and eight different drugs \\n(among which Paclitaxel, Docetaxel and Veliparib). The taxanes, Paclitaxel and \\nDocetaxel, were the only drugs having miRNAs in common: hsa-miR-187-5p and \\nhsa-miR-106a-3p indicative of drug resistance while Paclitaxel sensitivity alone \\nassociated with hsa-miR-556-5p. Tivantinib was associated with hsa-let-7d-5p and \\nhsa-miR-18a-5p for sensitivity and hsa-miR-637 for resistance. Drug sensitivity \\nwas associated with hsa-let-7a-5p for Bortezomib, hsa-miR-135a-3p for JNJ-707 \\nand hsa-miR-185-3p for Panobinostat. Drug resistance was associated with \\nhsa-miR-182-5p for Veliparib and hsa-miR-629-5p for Tipifarnib. Pathway analysis \\nfor significant miRNAs was performed to reveal biological roles, aiding to find \\na potential mechanistic link for the observed associations with drug response. \\nBy doing so hsa-miR-187-5p was linked to the cell cycle G2-M checkpoint in line \\nwith this checkpoint being the target of taxanes. In conclusion, our study shows \\nthat miRNAs could potentially serve as biomarkers for intrinsic drug resistance \\nand that pathway analyses can provide additional information in this context.'},\n",
       " 'doi': {0: 'DOI: 10.1080/10428194.2023.2278431\\nPMID: 37948578',\n",
       "  1: 'DOI: 10.3390/cells12182226\\nPMCID: PMC10526814\\nPMID: 37759449 [Indexed for MEDLINE]',\n",
       "  2: 'DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 37756570',\n",
       "  3: 'DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC10517900\\nPMID: 36879084 [Indexed for MEDLINE]',\n",
       "  4: 'DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841026 [Indexed for MEDLINE]',\n",
       "  5: 'DOI: 10.3390/ph16010111\\nPMCID: PMC9864669\\nPMID: 36678608',\n",
       "  6: 'DOI: 10.1016/j.leukres.2022.106967\\nPMID: 36270092 [Indexed for MEDLINE]',\n",
       "  7: 'DOI: 10.1097/CAD.0000000000001378\\nPMID: 36136989 [Indexed for MEDLINE]',\n",
       "  8: 'DOI: 10.1080/16078454.2022.2072062\\nPMID: 35617291 [Indexed for MEDLINE]',\n",
       "  9: 'DOI: 10.3390/cancers14071700\\nPMCID: PMC8997050\\nPMID: 35406472',\n",
       "  10: 'DOI: 10.1016/j.leukres.2022.106785\\nPMID: 35074616 [Indexed for MEDLINE]',\n",
       "  11: 'DOI: 10.1159/000518936\\nPMID: 35042223 [Indexed for MEDLINE]',\n",
       "  12: 'DOI: 10.1002/path.5852\\nPMID: 34919276 [Indexed for MEDLINE]',\n",
       "  13: 'DOI: 10.3389/fonc.2021.720261\\nPMCID: PMC8493032\\nPMID: 34631548',\n",
       "  14: 'DOI: 10.1097/CAD.0000000000001166\\nPMID: 34387610 [Indexed for MEDLINE]',\n",
       "  15: 'DOI: 10.2174/0929867328666210504104419\\nPMID: 33949926 [Indexed for MEDLINE]',\n",
       "  16: 'DOI: 10.2147/OTT.S286751\\nPMCID: PMC7814994\\nPMID: 33488100',\n",
       "  17: 'DOI: 10.1002/jcb.29684\\nPMID: 33417267 [Indexed for MEDLINE]',\n",
       "  18: 'DOI: 10.1002/cbin.11540\\nPMCID: PMC8248034\\nPMID: 33372728 [Indexed for MEDLINE]',\n",
       "  19: 'DOI: 10.3324/haematol.2019.227579\\nPMCID: PMC7716364\\nPMID: 33256380 [Indexed for MEDLINE]',\n",
       "  20: 'DOI: 10.1016/j.ejphar.2020.173752\\nPMID: 33253679 [Indexed for MEDLINE]',\n",
       "  21: 'DOI: 10.1080/15384101.2020.1839701\\nPMCID: PMC7751678\\nPMID: 33131409 [Indexed for MEDLINE]',\n",
       "  22: 'DOI: 10.1016/j.lfs.2020.118506\\nPMID: 33031827 [Indexed for MEDLINE]',\n",
       "  23: 'DOI: 10.3390/cancers12092569\\nPMCID: PMC7565855\\nPMID: 32916955',\n",
       "  24: 'DOI: 10.2147/CMAR.S241089\\nPMCID: PMC7094164\\nPMID: 32256118',\n",
       "  25: 'DOI: 10.1016/j.canlet.2020.03.020\\nPMID: 32220540 [Indexed for MEDLINE]',\n",
       "  26: 'DOI: 10.1186/s12885-019-6151-x\\nPMCID: PMC6805455\\nPMID: 31638931 [Indexed for MEDLINE]',\n",
       "  27: 'DOI: 10.1080/15384101.2019.1632138\\nPMCID: PMC6619958\\nPMID: 31204563 [Indexed for MEDLINE]',\n",
       "  28: 'DOI: 10.1016/j.bbrc.2019.05.078\\nPMID: 31103265 [Indexed for MEDLINE]',\n",
       "  29: 'DOI: 10.1371/journal.pone.0216400\\nPMCID: PMC6504094\\nPMID: 31063487 [Indexed for MEDLINE]'}}"
      ]
     },
     "execution_count": 303,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "new_df.to_dict()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 257,
   "metadata": {},
   "outputs": [],
   "source": [
    "text=\"\"\n",
    "with open(\"abstracts-bortezomib+resistance+mirna.txt\", \"r\",  encoding='utf-8') as abstracts_file:\n",
    "        text=abstracts_file.read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 258,
   "metadata": {},
   "outputs": [],
   "source": [
    "abstracts=text.split('\\n\\n\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 259,
   "metadata": {},
   "outputs": [],
   "source": [
    "abstracts_list=[]\n",
    "for abstract in abstracts:\n",
    "    abstracts_list.append(abstract.split('\\n\\n'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 260,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['']"
      ]
     },
     "execution_count": 260,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "abstracts_list.pop()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 281,
   "metadata": {},
   "outputs": [],
   "source": [
    "df=pd.DataFrame(abstracts_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 277,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     Circulating serum microRNAs as biomarkers of d...\n",
       "1     GPER1 Activation Exerts Anti-Tumor Activity in...\n",
       "2     Hypoxic bone marrow stromal cells secrete miR-...\n",
       "3     Bioinformatic Analysis of miR-200b/429 and Hub...\n",
       "4     miR-33b in human cancer: Mechanistic and clini...\n",
       "5     Review on Bortezomib Resistance in Multiple My...\n",
       "6     LncRNA MEG3 promotes the sensitivity of bortez...\n",
       "7     Circ_0005615 contributes to the progression an...\n",
       "8     Lncrna ANGPTL1-3 and its target microRNA-30a e...\n",
       "9     Circular RNA as a Novel Biomarker for Diagnosi...\n",
       "10    MiR-197-3p reduces bortezomib resistance in mu...\n",
       "11    miR-466 Contributes to the Enhanced Antitumor ...\n",
       "12    Myeloma cells regulate miRNA transfer from fib...\n",
       "13    Bortezomib Inhibits Multiple Myeloma Cells by ...\n",
       "14    Circular RNA circ-CCT3 promotes bortezomib res...\n",
       "15    MicroRNA in Multiple Myeloma - A Role in Patho...\n",
       "16    MicroRNA-1252-5p Associated with Extracellular...\n",
       "17    miR-218 contributes to drug resistance in mult...\n",
       "18    Exosomal mRNAs and lncRNAs involved in multipl...\n",
       "19    Targeting CD47/TNFAIP8 by miR-155 overcomes dr...\n",
       "20    Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedb...\n",
       "21    Depletion of circ_0007841 inhibits multiple my...\n",
       "22    CircRNA ITCH increases bortezomib sensitivity ...\n",
       "23    The Value of Serum MicroRNA Expression Signatu...\n",
       "24    hsa_circRNA_101237: A Novel Diagnostic and Pro...\n",
       "25    MARCKS inhibition cooperates with autophagy an...\n",
       "26    Ectopic expression of BIRC5-targeting miR-101-...\n",
       "27    miR-520g and miR-520h overcome bortezomib resi...\n",
       "28    Long non-coding RNA ANGPTL1-3 promotes multipl...\n",
       "29    MicroRNAs as possible indicators of drug sensi...\n",
       "Name: 1, dtype: object"
      ]
     },
     "execution_count": 277,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 282,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>6. Cancer Lett. 2020 Jun 28;480:29-38. doi: 10...</td>\n",
       "      <td>MARCKS inhibition cooperates with autophagy an...</td>\n",
       "      <td>Zhang L(1), Rastgoo N(1), Wu J(1), Zhang M(1),...</td>\n",
       "      <td>Author information:\\n(1)Department of Laborato...</td>\n",
       "      <td>Overexpression of Myristoylated Alanine-Rich C...</td>\n",
       "      <td>Copyright © 2020 Elsevier B.V. All rights rese...</td>\n",
       "      <td>DOI: 10.1016/j.canlet.2020.03.020\\nPMID: 32220...</td>\n",
       "      <td>Conflict of interest statement: Declaration of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>7. BMC Cancer. 2019 Oct 21;19(1):975. doi: 10....</td>\n",
       "      <td>Ectopic expression of BIRC5-targeting miR-101-...</td>\n",
       "      <td>Abdi J(1), Rastgoo N(1), Chen Y(1), Chen GA(2)...</td>\n",
       "      <td>Author information:\\n(1)Dept. of Laboratory He...</td>\n",
       "      <td>BACKGROUND: Multiple myeloma (MM) cells gain p...</td>\n",
       "      <td>DOI: 10.1186/s12885-019-6151-x\\nPMCID: PMC6805...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>8. Cell Cycle. 2019 Jul;18(14):1660-1669. doi:...</td>\n",
       "      <td>miR-520g and miR-520h overcome bortezomib resi...</td>\n",
       "      <td>Yuan X(1), Ma R(1), Yang S(1), Jiang L(1), Wan...</td>\n",
       "      <td>Author information:\\n(1)a Department of Hemato...</td>\n",
       "      <td>Background: Nowadays, microRNAs (miRNAs) attra...</td>\n",
       "      <td>DOI: 10.1080/15384101.2019.1632138\\nPMCID: PMC...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>9. Biochem Biophys Res Commun. 2019 Jul 5;514(...</td>\n",
       "      <td>Long non-coding RNA ANGPTL1-3 promotes multipl...</td>\n",
       "      <td>Nian F(1), Zhu J(2), Chang H(3).</td>\n",
       "      <td>Author information:\\n(1)School of Clinical Med...</td>\n",
       "      <td>Multiple Myeloma (MM) is a malignant hematolog...</td>\n",
       "      <td>Copyright © 2019 Elsevier Inc. All rights rese...</td>\n",
       "      <td>DOI: 10.1016/j.bbrc.2019.05.078\\nPMID: 3110326...</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>10. PLoS One. 2019 May 7;14(5):e0216400. doi: ...</td>\n",
       "      <td>MicroRNAs as possible indicators of drug sensi...</td>\n",
       "      <td>Uhr K(1), Prager-van der Smissen WJC(1), Heine...</td>\n",
       "      <td>Author information:\\n(1)Department of Medical ...</td>\n",
       "      <td>MicroRNAs (miRNAs) regulate gene expression po...</td>\n",
       "      <td>DOI: 10.1371/journal.pone.0216400\\nPMCID: PMC6...</td>\n",
       "      <td>Conflict of interest statement: I have read th...</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    0  \\\n",
       "25  6. Cancer Lett. 2020 Jun 28;480:29-38. doi: 10...   \n",
       "26  7. BMC Cancer. 2019 Oct 21;19(1):975. doi: 10....   \n",
       "27  8. Cell Cycle. 2019 Jul;18(14):1660-1669. doi:...   \n",
       "28  9. Biochem Biophys Res Commun. 2019 Jul 5;514(...   \n",
       "29  10. PLoS One. 2019 May 7;14(5):e0216400. doi: ...   \n",
       "\n",
       "                                                    1  \\\n",
       "25  MARCKS inhibition cooperates with autophagy an...   \n",
       "26  Ectopic expression of BIRC5-targeting miR-101-...   \n",
       "27  miR-520g and miR-520h overcome bortezomib resi...   \n",
       "28  Long non-coding RNA ANGPTL1-3 promotes multipl...   \n",
       "29  MicroRNAs as possible indicators of drug sensi...   \n",
       "\n",
       "                                                    2  \\\n",
       "25  Zhang L(1), Rastgoo N(1), Wu J(1), Zhang M(1),...   \n",
       "26  Abdi J(1), Rastgoo N(1), Chen Y(1), Chen GA(2)...   \n",
       "27  Yuan X(1), Ma R(1), Yang S(1), Jiang L(1), Wan...   \n",
       "28                   Nian F(1), Zhu J(2), Chang H(3).   \n",
       "29  Uhr K(1), Prager-van der Smissen WJC(1), Heine...   \n",
       "\n",
       "                                                    3  \\\n",
       "25  Author information:\\n(1)Department of Laborato...   \n",
       "26  Author information:\\n(1)Dept. of Laboratory He...   \n",
       "27  Author information:\\n(1)a Department of Hemato...   \n",
       "28  Author information:\\n(1)School of Clinical Med...   \n",
       "29  Author information:\\n(1)Department of Medical ...   \n",
       "\n",
       "                                                    4  \\\n",
       "25  Overexpression of Myristoylated Alanine-Rich C...   \n",
       "26  BACKGROUND: Multiple myeloma (MM) cells gain p...   \n",
       "27  Background: Nowadays, microRNAs (miRNAs) attra...   \n",
       "28  Multiple Myeloma (MM) is a malignant hematolog...   \n",
       "29  MicroRNAs (miRNAs) regulate gene expression po...   \n",
       "\n",
       "                                                    5  \\\n",
       "25  Copyright © 2020 Elsevier B.V. All rights rese...   \n",
       "26  DOI: 10.1186/s12885-019-6151-x\\nPMCID: PMC6805...   \n",
       "27  DOI: 10.1080/15384101.2019.1632138\\nPMCID: PMC...   \n",
       "28  Copyright © 2019 Elsevier Inc. All rights rese...   \n",
       "29  DOI: 10.1371/journal.pone.0216400\\nPMCID: PMC6...   \n",
       "\n",
       "                                                    6  \\\n",
       "25  DOI: 10.1016/j.canlet.2020.03.020\\nPMID: 32220...   \n",
       "26  Conflict of interest statement: The authors de...   \n",
       "27                                               None   \n",
       "28  DOI: 10.1016/j.bbrc.2019.05.078\\nPMID: 3110326...   \n",
       "29  Conflict of interest statement: I have read th...   \n",
       "\n",
       "                                                    7  \n",
       "25  Conflict of interest statement: Declaration of...  \n",
       "26                                               None  \n",
       "27                                               None  \n",
       "28                                               None  \n",
       "29                                               None  "
      ]
     },
     "execution_count": 282,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.tail()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 252,
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(0,df.shape[0]):\n",
    "    df.iloc[i,4]=df.iloc[i,4].lstrip()\n",
    "    if(df.iloc[i,4].startswith('Comment') or df.iloc[i,4].startswith('Erratum') or df.iloc[i,4].startswith('Update') or df.iloc[i,4].startswith('Author')):\n",
    "        df.iloc[i,4]=df.iloc[i,5]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 265,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_excel(\"sample3.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 299,
   "metadata": {},
   "outputs": [],
   "source": [
    "def createWordCloud(content):\n",
    "    comment_words = ''\n",
    "    stopwords = set(STOPWORDS)\n",
    "\n",
    "    # iterate through the csv file\n",
    "    for val in content:\n",
    "\n",
    "        # typecaste each val to string\n",
    "        val = str(val)\n",
    "\n",
    "        # split the value\n",
    "        tokens = val.split()\n",
    "\n",
    "        # Converts each token into lowercase\n",
    "        for i in range(len(tokens)):\n",
    "            tokens[i] = tokens[i].lower()\n",
    "\n",
    "        comment_words += \" \".join(tokens)+\" \"\n",
    "\n",
    "    wordcloud = WordCloud(width = 800, height = 800,\n",
    "                    background_color ='white',\n",
    "                    stopwords = stopwords,\n",
    "                    min_font_size = 10).generate(comment_words)\n",
    "    # plot the WordCloud image                       \n",
    "    plt.figure(figsize = (8, 8), facecolor = None)\n",
    "    plt.imshow(wordcloud)\n",
    "    plt.axis(\"off\")\n",
    "    plt.tight_layout(pad = 0)\n",
    "    plt.savefig('cloud.png')\n",
    "    plt.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 300,
   "metadata": {},
   "outputs": [],
   "source": [
    "createWordCloud(df.iloc[:,4])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 268,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 576x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "createWordCloud(df.iloc[:,1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "metadata": {},
   "outputs": [],
   "source": [
    "def find_doi(row):\n",
    "    for col in row[5:]:  # Adjusted to start from the 5th column (index 4) to the end\n",
    "        if col.lstrip().startswith('DOI'):\n",
    "            return col\n",
    "    return 'no link'\n",
    "\n",
    "df['doi'] = df.apply(find_doi, axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 284,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>doi</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1. Leuk Lymphoma. 2023 Nov 10:1-8. doi: 10.108...</td>\n",
       "      <td>Circulating serum microRNAs as biomarkers of d...</td>\n",
       "      <td>Puła A(1)(2), Robak T(1)(3), Dróżdż I(4), Staw...</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Despite advances in multiple myeloma (MM) trea...</td>\n",
       "      <td>DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2. Cells. 2023 Sep 7;12(18):2226. doi: 10.3390...</td>\n",
       "      <td>GPER1 Activation Exerts Anti-Tumor Activity in...</td>\n",
       "      <td>Gallo Cantafio ME(1), Torcasio R(1)(2), Sciont...</td>\n",
       "      <td>Author information:\\n(1)Department of Experime...</td>\n",
       "      <td>G protein-coupled estrogen receptor 1 (GPER1) ...</td>\n",
       "      <td>DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3. Cancer Res. 2023 Sep 26. doi: 10.1158/0008-...</td>\n",
       "      <td>Hypoxic bone marrow stromal cells secrete miR-...</td>\n",
       "      <td>Zhang H(1), Du Z(2), Tu C(2), Zhou X(1), Menu ...</td>\n",
       "      <td>Author information:\\n(1)Guangzhou Medical Univ...</td>\n",
       "      <td>Bone marrow stromal cell (BMSC)-derived small ...</td>\n",
       "      <td>DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4. Biochem Genet. 2023 Oct;61(5):1898-1916. do...</td>\n",
       "      <td>Bioinformatic Analysis of miR-200b/429 and Hub...</td>\n",
       "      <td>Shukla V(1), Mallya S(2), Adiga D(1), Sriharik...</td>\n",
       "      <td>Author information:\\n(1)Department of Cell and...</td>\n",
       "      <td>The miR-200b/429 located at 1p36 is a highly c...</td>\n",
       "      <td>© 2023. The Author(s).</td>\n",
       "      <td>DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5. Biomed Pharmacother. 2023 May;161:114432. d...</td>\n",
       "      <td>miR-33b in human cancer: Mechanistic and clini...</td>\n",
       "      <td>Zhang W(1), Jiang B(2), Zhu H(3), Cheng A(2), ...</td>\n",
       "      <td>Author information:\\n(1)Department of Neurosur...</td>\n",
       "      <td>The microRNAs (miRNAs), an extensive class of ...</td>\n",
       "      <td>Copyright © 2023 The Authors. Published by Els...</td>\n",
       "      <td>DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...</td>\n",
       "      <td>Conflict of interest statement: Conflict of In...</td>\n",
       "      <td>DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                   0  \\\n",
       "0  1. Leuk Lymphoma. 2023 Nov 10:1-8. doi: 10.108...   \n",
       "1  2. Cells. 2023 Sep 7;12(18):2226. doi: 10.3390...   \n",
       "2  3. Cancer Res. 2023 Sep 26. doi: 10.1158/0008-...   \n",
       "3  4. Biochem Genet. 2023 Oct;61(5):1898-1916. do...   \n",
       "4  5. Biomed Pharmacother. 2023 May;161:114432. d...   \n",
       "\n",
       "                                                   1  \\\n",
       "0  Circulating serum microRNAs as biomarkers of d...   \n",
       "1  GPER1 Activation Exerts Anti-Tumor Activity in...   \n",
       "2  Hypoxic bone marrow stromal cells secrete miR-...   \n",
       "3  Bioinformatic Analysis of miR-200b/429 and Hub...   \n",
       "4  miR-33b in human cancer: Mechanistic and clini...   \n",
       "\n",
       "                                                   2  \\\n",
       "0  Puła A(1)(2), Robak T(1)(3), Dróżdż I(4), Staw...   \n",
       "1  Gallo Cantafio ME(1), Torcasio R(1)(2), Sciont...   \n",
       "2  Zhang H(1), Du Z(2), Tu C(2), Zhou X(1), Menu ...   \n",
       "3  Shukla V(1), Mallya S(2), Adiga D(1), Sriharik...   \n",
       "4  Zhang W(1), Jiang B(2), Zhu H(3), Cheng A(2), ...   \n",
       "\n",
       "                                                   3  \\\n",
       "0  Author information:\\n(1)Department of Hematolo...   \n",
       "1  Author information:\\n(1)Department of Experime...   \n",
       "2  Author information:\\n(1)Guangzhou Medical Univ...   \n",
       "3  Author information:\\n(1)Department of Cell and...   \n",
       "4  Author information:\\n(1)Department of Neurosur...   \n",
       "\n",
       "                                                   4  \\\n",
       "0  Despite advances in multiple myeloma (MM) trea...   \n",
       "1  G protein-coupled estrogen receptor 1 (GPER1) ...   \n",
       "2  Bone marrow stromal cell (BMSC)-derived small ...   \n",
       "3  The miR-200b/429 located at 1p36 is a highly c...   \n",
       "4  The microRNAs (miRNAs), an extensive class of ...   \n",
       "\n",
       "                                                   5  \\\n",
       "0  DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...   \n",
       "1  DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...   \n",
       "2  DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...   \n",
       "3                             © 2023. The Author(s).   \n",
       "4  Copyright © 2023 The Authors. Published by Els...   \n",
       "\n",
       "                                                   6  \\\n",
       "0                                               None   \n",
       "1  Conflict of interest statement: The authors de...   \n",
       "2                                               None   \n",
       "3  DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...   \n",
       "4  DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...   \n",
       "\n",
       "                                                   7  \\\n",
       "0                                               None   \n",
       "1                                               None   \n",
       "2                                               None   \n",
       "3  Conflict of interest statement: The authors de...   \n",
       "4  Conflict of interest statement: Conflict of In...   \n",
       "\n",
       "                                                 doi  \n",
       "0  DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...  \n",
       "1  DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...  \n",
       "2  DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...  \n",
       "3  DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...  \n",
       "4  DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...  "
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 285,
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_index(title):\n",
    "    # Use regular expression to remove the index number and following dot and space\n",
    "    # Pattern explanation:\n",
    "    # ^ - start of the string\n",
    "    # \\d+ - one or more digits\n",
    "    # \\. - a literal dot\n",
    "    # \\s - any whitespace character\n",
    "    # - the above pattern is then replaced with an empty string\n",
    "    cleaned_title = re.sub(r'^\\d+\\.\\s', '', title)\n",
    "    return cleaned_title\n",
    "\n",
    "df[0] = df[0].apply(remove_index)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 286,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>doi</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Leuk Lymphoma. 2023 Nov 10:1-8. doi: 10.1080/1...</td>\n",
       "      <td>Circulating serum microRNAs as biomarkers of d...</td>\n",
       "      <td>Puła A(1)(2), Robak T(1)(3), Dróżdż I(4), Staw...</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Despite advances in multiple myeloma (MM) trea...</td>\n",
       "      <td>DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cells. 2023 Sep 7;12(18):2226. doi: 10.3390/ce...</td>\n",
       "      <td>GPER1 Activation Exerts Anti-Tumor Activity in...</td>\n",
       "      <td>Gallo Cantafio ME(1), Torcasio R(1)(2), Sciont...</td>\n",
       "      <td>Author information:\\n(1)Department of Experime...</td>\n",
       "      <td>G protein-coupled estrogen receptor 1 (GPER1) ...</td>\n",
       "      <td>DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Cancer Res. 2023 Sep 26. doi: 10.1158/0008-547...</td>\n",
       "      <td>Hypoxic bone marrow stromal cells secrete miR-...</td>\n",
       "      <td>Zhang H(1), Du Z(2), Tu C(2), Zhou X(1), Menu ...</td>\n",
       "      <td>Author information:\\n(1)Guangzhou Medical Univ...</td>\n",
       "      <td>Bone marrow stromal cell (BMSC)-derived small ...</td>\n",
       "      <td>DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Biochem Genet. 2023 Oct;61(5):1898-1916. doi: ...</td>\n",
       "      <td>Bioinformatic Analysis of miR-200b/429 and Hub...</td>\n",
       "      <td>Shukla V(1), Mallya S(2), Adiga D(1), Sriharik...</td>\n",
       "      <td>Author information:\\n(1)Department of Cell and...</td>\n",
       "      <td>The miR-200b/429 located at 1p36 is a highly c...</td>\n",
       "      <td>© 2023. The Author(s).</td>\n",
       "      <td>DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Biomed Pharmacother. 2023 May;161:114432. doi:...</td>\n",
       "      <td>miR-33b in human cancer: Mechanistic and clini...</td>\n",
       "      <td>Zhang W(1), Jiang B(2), Zhu H(3), Cheng A(2), ...</td>\n",
       "      <td>Author information:\\n(1)Department of Neurosur...</td>\n",
       "      <td>The microRNAs (miRNAs), an extensive class of ...</td>\n",
       "      <td>Copyright © 2023 The Authors. Published by Els...</td>\n",
       "      <td>DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...</td>\n",
       "      <td>Conflict of interest statement: Conflict of In...</td>\n",
       "      <td>DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Pharmaceuticals (Basel). 2023 Jan 12;16(1):111...</td>\n",
       "      <td>Review on Bortezomib Resistance in Multiple My...</td>\n",
       "      <td>Kozalak G(1)(2), Bütün İ(1), Toyran E(1), Koşa...</td>\n",
       "      <td>Author information:\\n(1)Faculty of Engineering...</td>\n",
       "      <td>Multiple myeloma is a hematological cancer typ...</td>\n",
       "      <td>DOI: 10.3390/ph16010111\\nPMCID: PMC9864669\\nPM...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.3390/ph16010111\\nPMCID: PMC9864669\\nPM...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Leuk Res. 2022 Dec;123:106967. doi: 10.1016/j....</td>\n",
       "      <td>LncRNA MEG3 promotes the sensitivity of bortez...</td>\n",
       "      <td>Zang X(1), Wang J(1), Xia Y(1), Li J(1), Chen ...</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>BACKGROUND: Bortezomib resistance hampers the ...</td>\n",
       "      <td>Copyright © 2022 The Authors. Published by Els...</td>\n",
       "      <td>DOI: 10.1016/j.leukres.2022.106967\\nPMID: 3627...</td>\n",
       "      <td>Conflict of interest statement: Declaration of...</td>\n",
       "      <td>DOI: 10.1016/j.leukres.2022.106967\\nPMID: 3627...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Anticancer Drugs. 2022 Oct 1;33(9):893-902. do...</td>\n",
       "      <td>Circ_0005615 contributes to the progression an...</td>\n",
       "      <td>Fu C(1), Wang J, Hu M, Zhou W.</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Circular RNAs (circRNAs) have been shown to pl...</td>\n",
       "      <td>Copyright © 2022 Wolters Kluwer Health, Inc. A...</td>\n",
       "      <td>DOI: 10.1097/CAD.0000000000001378\\nPMID: 36136...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1097/CAD.0000000000001378\\nPMID: 36136...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Hematology. 2022 Dec;27(1):596-602. doi: 10.10...</td>\n",
       "      <td>Lncrna ANGPTL1-3 and its target microRNA-30a e...</td>\n",
       "      <td>Zhou F(1), Guo L(1).</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>OBJECTIVE: Long non-coding RNA ANGPTL1-3 (lnc-...</td>\n",
       "      <td>DOI: 10.1080/16078454.2022.2072062\\nPMID: 3561...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1080/16078454.2022.2072062\\nPMID: 3561...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Cancers (Basel). 2022 Mar 27;14(7):1700. doi: ...</td>\n",
       "      <td>Circular RNA as a Novel Biomarker for Diagnosi...</td>\n",
       "      <td>Allegra A(1), Cicero N(2), Tonacci A(3), Musol...</td>\n",
       "      <td>Author information:\\n(1)Department of Human Pa...</td>\n",
       "      <td>Circular RNAs (circRNAs) are a novel type of c...</td>\n",
       "      <td>DOI: 10.3390/cancers14071700\\nPMCID: PMC899705...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.3390/cancers14071700\\nPMCID: PMC899705...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Leuk Res. 2022 Mar;114:106785. doi: 10.1016/j....</td>\n",
       "      <td>MiR-197-3p reduces bortezomib resistance in mu...</td>\n",
       "      <td>Liu Y(1), Cheng P(1), Zhao W(1), Zhu L(2), Sui...</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>OBJECTIVE: This study investigated the mechani...</td>\n",
       "      <td>Copyright © 2022 Elsevier Ltd. All rights rese...</td>\n",
       "      <td>DOI: 10.1016/j.leukres.2022.106785\\nPMID: 3507...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1016/j.leukres.2022.106785\\nPMID: 3507...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Chemotherapy. 2022;67(2):110-122. doi: 10.1159...</td>\n",
       "      <td>miR-466 Contributes to the Enhanced Antitumor ...</td>\n",
       "      <td>Wang WH(1), Zhan JM(1), Tang YL(1), Zhou N(1),...</td>\n",
       "      <td>Author information:\\n(1)Department of Thoracic...</td>\n",
       "      <td>INTRODUCTION: Changes in microRNAs (miRs) cont...</td>\n",
       "      <td>© 2022 S. Karger AG, Basel.</td>\n",
       "      <td>DOI: 10.1159/000518936\\nPMID: 35042223 [Indexe...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1159/000518936\\nPMID: 35042223 [Indexe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>J Pathol. 2022 Apr;256(4):402-413. doi: 10.100...</td>\n",
       "      <td>Myeloma cells regulate miRNA transfer from fib...</td>\n",
       "      <td>Saltarella I(1), Lamanuzzi A(1), Desantis V(1)...</td>\n",
       "      <td>Author information:\\n(1)Department of Biomedic...</td>\n",
       "      <td>Multiple myeloma (MM) progression and drug res...</td>\n",
       "      <td>© 2021 The Pathological Society of Great Brita...</td>\n",
       "      <td>DOI: 10.1002/path.5852\\nPMID: 34919276 [Indexe...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1002/path.5852\\nPMID: 34919276 [Indexe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Front Oncol. 2021 Sep 22;11:720261. doi: 10.33...</td>\n",
       "      <td>Bortezomib Inhibits Multiple Myeloma Cells by ...</td>\n",
       "      <td>Lai X(1), Huang C(2), Nie X(3), Chen Q(1), Tan...</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Multiple myeloma (MM) is a malignant cancer wi...</td>\n",
       "      <td>Copyright © 2021 Lai, Huang, Nie, Chen, Tang, ...</td>\n",
       "      <td>DOI: 10.3389/fonc.2021.720261\\nPMCID: PMC84930...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>DOI: 10.3389/fonc.2021.720261\\nPMCID: PMC84930...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Anticancer Drugs. 2022 Jan 1;33(1):e145-e154. ...</td>\n",
       "      <td>Circular RNA circ-CCT3 promotes bortezomib res...</td>\n",
       "      <td>Liu D(1), Wang Y, Li H, Peng S, Tan H, Huang Z.</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Multiple myeloma is a frequent hematologic mal...</td>\n",
       "      <td>Copyright © 2021 Wolters Kluwer Health, Inc. A...</td>\n",
       "      <td>DOI: 10.1097/CAD.0000000000001166\\nPMID: 34387...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1097/CAD.0000000000001166\\nPMID: 34387...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Curr Med Chem. 2021 Oct 25;28(33):6753-6772. d...</td>\n",
       "      <td>MicroRNA in Multiple Myeloma - A Role in Patho...</td>\n",
       "      <td>Puła A(1), Robak P(1), Robak T(1).</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Multiple myeloma (MM) is a common malignant he...</td>\n",
       "      <td>Copyright© Bentham Science Publishers; For any...</td>\n",
       "      <td>DOI: 10.2174/0929867328666210504104419\\nPMID: ...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.2174/0929867328666210504104419\\nPMID: ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Onco Targets Ther. 2021 Jan 15;14:455-467. doi...</td>\n",
       "      <td>MicroRNA-1252-5p Associated with Extracellular...</td>\n",
       "      <td>Rodrigues-Junior DM(1)(2), Pelarin MFA(1), Nad...</td>\n",
       "      <td>Author information:\\n(1)Department of Biochemi...</td>\n",
       "      <td>INTRODUCTION: Multiple myeloma (MM) remains an...</td>\n",
       "      <td>© 2021 Rodrigues-Junior et al.</td>\n",
       "      <td>DOI: 10.2147/OTT.S286751\\nPMCID: PMC7814994\\nP...</td>\n",
       "      <td>Conflict of interest statement: Maria Aparecid...</td>\n",
       "      <td>DOI: 10.2147/OTT.S286751\\nPMCID: PMC7814994\\nP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>J Cell Biochem. 2021 Apr;122(3-4):305-314. doi...</td>\n",
       "      <td>miR-218 contributes to drug resistance in mult...</td>\n",
       "      <td>Chen H(1), Cao W(2), Chen J(1), Liu D(1), Zhou...</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Multiple myeloma (MM) is a malignant neoplasm ...</td>\n",
       "      <td>© 2020 Wiley Periodicals, Inc.</td>\n",
       "      <td>DOI: 10.1002/jcb.29684\\nPMID: 33417267 [Indexe...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1002/jcb.29684\\nPMID: 33417267 [Indexe...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Cell Biol Int. 2021 May;45(5):965-975. doi: 10...</td>\n",
       "      <td>Exosomal mRNAs and lncRNAs involved in multipl...</td>\n",
       "      <td>Tang JX(1), Chen Q(1), Li Q(2), He YH(2), Xiao...</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>The bone marrow microenvironment plays an esse...</td>\n",
       "      <td>© 2021 The Authors. Cell Biology International...</td>\n",
       "      <td>DOI: 10.1002/cbin.11540\\nPMCID: PMC8248034\\nPM...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>DOI: 10.1002/cbin.11540\\nPMCID: PMC8248034\\nPM...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Haematologica. 2020 Dec 1;105(12):2813-2823. d...</td>\n",
       "      <td>Targeting CD47/TNFAIP8 by miR-155 overcomes dr...</td>\n",
       "      <td>Rastgoo N(1), Wu J(1), Liu A(2), Pourabdollah ...</td>\n",
       "      <td>Author information:\\n(1)Department of Laborato...</td>\n",
       "      <td>The mechanisms of drug resistance in multiple ...</td>\n",
       "      <td>DOI: 10.3324/haematol.2019.227579\\nPMCID: PMC7...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.3324/haematol.2019.227579\\nPMCID: PMC7...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Eur J Pharmacol. 2021 Jan 15;891:173752. doi: ...</td>\n",
       "      <td>Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedb...</td>\n",
       "      <td>Che F(1), Ye X(2), Wang Y(2), Ma S(2), Wang X(2).</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>The overall survival of multiple myeloma (MM) ...</td>\n",
       "      <td>Copyright © 2020 Elsevier B.V. All rights rese...</td>\n",
       "      <td>DOI: 10.1016/j.ejphar.2020.173752\\nPMID: 33253...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1016/j.ejphar.2020.173752\\nPMID: 33253...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Cell Cycle. 2020 Dec;19(23):3289-3302. doi: 10...</td>\n",
       "      <td>Depletion of circ_0007841 inhibits multiple my...</td>\n",
       "      <td>Wang Y(1), Lin Q(2), Song C(1), Ma R(1), Li X(1).</td>\n",
       "      <td>Author information:\\n(1)Department of Hematolo...</td>\n",
       "      <td>Circular RNAs (circRNAs) possess important reg...</td>\n",
       "      <td>DOI: 10.1080/15384101.2020.1839701\\nPMCID: PMC...</td>\n",
       "      <td>Conflict of interest statement: The authors ha...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1080/15384101.2020.1839701\\nPMCID: PMC...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Life Sci. 2020 Dec 1;262:118506. doi: 10.1016/...</td>\n",
       "      <td>CircRNA ITCH increases bortezomib sensitivity ...</td>\n",
       "      <td>Liu J(1), Du F(2), Chen C(1), Li D(1), Chen Y(...</td>\n",
       "      <td>Author information:\\n(1)Orthopaedics Departmen...</td>\n",
       "      <td>AIMS: Bortezomib (BTZ) is described as the fir...</td>\n",
       "      <td>Copyright © 2020 Elsevier Inc. All rights rese...</td>\n",
       "      <td>DOI: 10.1016/j.lfs.2020.118506\\nPMID: 33031827...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1016/j.lfs.2020.118506\\nPMID: 33031827...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Cancers (Basel). 2020 Sep 9;12(9):2569. doi: 1...</td>\n",
       "      <td>The Value of Serum MicroRNA Expression Signatu...</td>\n",
       "      <td>Robak P(1), Dróżdż I(2), Jarych D(3), Mikulski...</td>\n",
       "      <td>Author information:\\n(1)Department of Experime...</td>\n",
       "      <td>Bortezomib is the first-in-class proteasome in...</td>\n",
       "      <td>DOI: 10.3390/cancers12092569\\nPMCID: PMC756585...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.3390/cancers12092569\\nPMCID: PMC756585...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Cancer Manag Res. 2020 Mar 20;12:2109-2118. do...</td>\n",
       "      <td>hsa_circRNA_101237: A Novel Diagnostic and Pro...</td>\n",
       "      <td>Liu X(#)(1), Tang H(#)(1), Liu J(1), Wang X(2).</td>\n",
       "      <td>Author information:\\n(1)The Third Xiangya Hosp...</td>\n",
       "      <td>BACKGROUND: It has been demonstrated that circ...</td>\n",
       "      <td>© 2020 Liu et al.</td>\n",
       "      <td>DOI: 10.2147/CMAR.S241089\\nPMCID: PMC7094164\\n...</td>\n",
       "      <td>Conflict of interest statement: The authors re...</td>\n",
       "      <td>DOI: 10.2147/CMAR.S241089\\nPMCID: PMC7094164\\n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Cancer Lett. 2020 Jun 28;480:29-38. doi: 10.10...</td>\n",
       "      <td>MARCKS inhibition cooperates with autophagy an...</td>\n",
       "      <td>Zhang L(1), Rastgoo N(1), Wu J(1), Zhang M(1),...</td>\n",
       "      <td>Author information:\\n(1)Department of Laborato...</td>\n",
       "      <td>Overexpression of Myristoylated Alanine-Rich C...</td>\n",
       "      <td>Copyright © 2020 Elsevier B.V. All rights rese...</td>\n",
       "      <td>DOI: 10.1016/j.canlet.2020.03.020\\nPMID: 32220...</td>\n",
       "      <td>Conflict of interest statement: Declaration of...</td>\n",
       "      <td>DOI: 10.1016/j.canlet.2020.03.020\\nPMID: 32220...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>BMC Cancer. 2019 Oct 21;19(1):975. doi: 10.118...</td>\n",
       "      <td>Ectopic expression of BIRC5-targeting miR-101-...</td>\n",
       "      <td>Abdi J(1), Rastgoo N(1), Chen Y(1), Chen GA(2)...</td>\n",
       "      <td>Author information:\\n(1)Dept. of Laboratory He...</td>\n",
       "      <td>BACKGROUND: Multiple myeloma (MM) cells gain p...</td>\n",
       "      <td>DOI: 10.1186/s12885-019-6151-x\\nPMCID: PMC6805...</td>\n",
       "      <td>Conflict of interest statement: The authors de...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1186/s12885-019-6151-x\\nPMCID: PMC6805...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Cell Cycle. 2019 Jul;18(14):1660-1669. doi: 10...</td>\n",
       "      <td>miR-520g and miR-520h overcome bortezomib resi...</td>\n",
       "      <td>Yuan X(1), Ma R(1), Yang S(1), Jiang L(1), Wan...</td>\n",
       "      <td>Author information:\\n(1)a Department of Hemato...</td>\n",
       "      <td>Background: Nowadays, microRNAs (miRNAs) attra...</td>\n",
       "      <td>DOI: 10.1080/15384101.2019.1632138\\nPMCID: PMC...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1080/15384101.2019.1632138\\nPMCID: PMC...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Biochem Biophys Res Commun. 2019 Jul 5;514(4):...</td>\n",
       "      <td>Long non-coding RNA ANGPTL1-3 promotes multipl...</td>\n",
       "      <td>Nian F(1), Zhu J(2), Chang H(3).</td>\n",
       "      <td>Author information:\\n(1)School of Clinical Med...</td>\n",
       "      <td>Multiple Myeloma (MM) is a malignant hematolog...</td>\n",
       "      <td>Copyright © 2019 Elsevier Inc. All rights rese...</td>\n",
       "      <td>DOI: 10.1016/j.bbrc.2019.05.078\\nPMID: 3110326...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1016/j.bbrc.2019.05.078\\nPMID: 3110326...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>PLoS One. 2019 May 7;14(5):e0216400. doi: 10.1...</td>\n",
       "      <td>MicroRNAs as possible indicators of drug sensi...</td>\n",
       "      <td>Uhr K(1), Prager-van der Smissen WJC(1), Heine...</td>\n",
       "      <td>Author information:\\n(1)Department of Medical ...</td>\n",
       "      <td>MicroRNAs (miRNAs) regulate gene expression po...</td>\n",
       "      <td>DOI: 10.1371/journal.pone.0216400\\nPMCID: PMC6...</td>\n",
       "      <td>Conflict of interest statement: I have read th...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOI: 10.1371/journal.pone.0216400\\nPMCID: PMC6...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    0  \\\n",
       "0   Leuk Lymphoma. 2023 Nov 10:1-8. doi: 10.1080/1...   \n",
       "1   Cells. 2023 Sep 7;12(18):2226. doi: 10.3390/ce...   \n",
       "2   Cancer Res. 2023 Sep 26. doi: 10.1158/0008-547...   \n",
       "3   Biochem Genet. 2023 Oct;61(5):1898-1916. doi: ...   \n",
       "4   Biomed Pharmacother. 2023 May;161:114432. doi:...   \n",
       "5   Pharmaceuticals (Basel). 2023 Jan 12;16(1):111...   \n",
       "6   Leuk Res. 2022 Dec;123:106967. doi: 10.1016/j....   \n",
       "7   Anticancer Drugs. 2022 Oct 1;33(9):893-902. do...   \n",
       "8   Hematology. 2022 Dec;27(1):596-602. doi: 10.10...   \n",
       "9   Cancers (Basel). 2022 Mar 27;14(7):1700. doi: ...   \n",
       "10  Leuk Res. 2022 Mar;114:106785. doi: 10.1016/j....   \n",
       "11  Chemotherapy. 2022;67(2):110-122. doi: 10.1159...   \n",
       "12  J Pathol. 2022 Apr;256(4):402-413. doi: 10.100...   \n",
       "13  Front Oncol. 2021 Sep 22;11:720261. doi: 10.33...   \n",
       "14  Anticancer Drugs. 2022 Jan 1;33(1):e145-e154. ...   \n",
       "15  Curr Med Chem. 2021 Oct 25;28(33):6753-6772. d...   \n",
       "16  Onco Targets Ther. 2021 Jan 15;14:455-467. doi...   \n",
       "17  J Cell Biochem. 2021 Apr;122(3-4):305-314. doi...   \n",
       "18  Cell Biol Int. 2021 May;45(5):965-975. doi: 10...   \n",
       "19  Haematologica. 2020 Dec 1;105(12):2813-2823. d...   \n",
       "20  Eur J Pharmacol. 2021 Jan 15;891:173752. doi: ...   \n",
       "21  Cell Cycle. 2020 Dec;19(23):3289-3302. doi: 10...   \n",
       "22  Life Sci. 2020 Dec 1;262:118506. doi: 10.1016/...   \n",
       "23  Cancers (Basel). 2020 Sep 9;12(9):2569. doi: 1...   \n",
       "24  Cancer Manag Res. 2020 Mar 20;12:2109-2118. do...   \n",
       "25  Cancer Lett. 2020 Jun 28;480:29-38. doi: 10.10...   \n",
       "26  BMC Cancer. 2019 Oct 21;19(1):975. doi: 10.118...   \n",
       "27  Cell Cycle. 2019 Jul;18(14):1660-1669. doi: 10...   \n",
       "28  Biochem Biophys Res Commun. 2019 Jul 5;514(4):...   \n",
       "29  PLoS One. 2019 May 7;14(5):e0216400. doi: 10.1...   \n",
       "\n",
       "                                                    1  \\\n",
       "0   Circulating serum microRNAs as biomarkers of d...   \n",
       "1   GPER1 Activation Exerts Anti-Tumor Activity in...   \n",
       "2   Hypoxic bone marrow stromal cells secrete miR-...   \n",
       "3   Bioinformatic Analysis of miR-200b/429 and Hub...   \n",
       "4   miR-33b in human cancer: Mechanistic and clini...   \n",
       "5   Review on Bortezomib Resistance in Multiple My...   \n",
       "6   LncRNA MEG3 promotes the sensitivity of bortez...   \n",
       "7   Circ_0005615 contributes to the progression an...   \n",
       "8   Lncrna ANGPTL1-3 and its target microRNA-30a e...   \n",
       "9   Circular RNA as a Novel Biomarker for Diagnosi...   \n",
       "10  MiR-197-3p reduces bortezomib resistance in mu...   \n",
       "11  miR-466 Contributes to the Enhanced Antitumor ...   \n",
       "12  Myeloma cells regulate miRNA transfer from fib...   \n",
       "13  Bortezomib Inhibits Multiple Myeloma Cells by ...   \n",
       "14  Circular RNA circ-CCT3 promotes bortezomib res...   \n",
       "15  MicroRNA in Multiple Myeloma - A Role in Patho...   \n",
       "16  MicroRNA-1252-5p Associated with Extracellular...   \n",
       "17  miR-218 contributes to drug resistance in mult...   \n",
       "18  Exosomal mRNAs and lncRNAs involved in multipl...   \n",
       "19  Targeting CD47/TNFAIP8 by miR-155 overcomes dr...   \n",
       "20  Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedb...   \n",
       "21  Depletion of circ_0007841 inhibits multiple my...   \n",
       "22  CircRNA ITCH increases bortezomib sensitivity ...   \n",
       "23  The Value of Serum MicroRNA Expression Signatu...   \n",
       "24  hsa_circRNA_101237: A Novel Diagnostic and Pro...   \n",
       "25  MARCKS inhibition cooperates with autophagy an...   \n",
       "26  Ectopic expression of BIRC5-targeting miR-101-...   \n",
       "27  miR-520g and miR-520h overcome bortezomib resi...   \n",
       "28  Long non-coding RNA ANGPTL1-3 promotes multipl...   \n",
       "29  MicroRNAs as possible indicators of drug sensi...   \n",
       "\n",
       "                                                    2  \\\n",
       "0   Puła A(1)(2), Robak T(1)(3), Dróżdż I(4), Staw...   \n",
       "1   Gallo Cantafio ME(1), Torcasio R(1)(2), Sciont...   \n",
       "2   Zhang H(1), Du Z(2), Tu C(2), Zhou X(1), Menu ...   \n",
       "3   Shukla V(1), Mallya S(2), Adiga D(1), Sriharik...   \n",
       "4   Zhang W(1), Jiang B(2), Zhu H(3), Cheng A(2), ...   \n",
       "5   Kozalak G(1)(2), Bütün İ(1), Toyran E(1), Koşa...   \n",
       "6   Zang X(1), Wang J(1), Xia Y(1), Li J(1), Chen ...   \n",
       "7                      Fu C(1), Wang J, Hu M, Zhou W.   \n",
       "8                                Zhou F(1), Guo L(1).   \n",
       "9   Allegra A(1), Cicero N(2), Tonacci A(3), Musol...   \n",
       "10  Liu Y(1), Cheng P(1), Zhao W(1), Zhu L(2), Sui...   \n",
       "11  Wang WH(1), Zhan JM(1), Tang YL(1), Zhou N(1),...   \n",
       "12  Saltarella I(1), Lamanuzzi A(1), Desantis V(1)...   \n",
       "13  Lai X(1), Huang C(2), Nie X(3), Chen Q(1), Tan...   \n",
       "14    Liu D(1), Wang Y, Li H, Peng S, Tan H, Huang Z.   \n",
       "15                 Puła A(1), Robak P(1), Robak T(1).   \n",
       "16  Rodrigues-Junior DM(1)(2), Pelarin MFA(1), Nad...   \n",
       "17  Chen H(1), Cao W(2), Chen J(1), Liu D(1), Zhou...   \n",
       "18  Tang JX(1), Chen Q(1), Li Q(2), He YH(2), Xiao...   \n",
       "19  Rastgoo N(1), Wu J(1), Liu A(2), Pourabdollah ...   \n",
       "20  Che F(1), Ye X(2), Wang Y(2), Ma S(2), Wang X(2).   \n",
       "21  Wang Y(1), Lin Q(2), Song C(1), Ma R(1), Li X(1).   \n",
       "22  Liu J(1), Du F(2), Chen C(1), Li D(1), Chen Y(...   \n",
       "23  Robak P(1), Dróżdż I(2), Jarych D(3), Mikulski...   \n",
       "24    Liu X(#)(1), Tang H(#)(1), Liu J(1), Wang X(2).   \n",
       "25  Zhang L(1), Rastgoo N(1), Wu J(1), Zhang M(1),...   \n",
       "26  Abdi J(1), Rastgoo N(1), Chen Y(1), Chen GA(2)...   \n",
       "27  Yuan X(1), Ma R(1), Yang S(1), Jiang L(1), Wan...   \n",
       "28                   Nian F(1), Zhu J(2), Chang H(3).   \n",
       "29  Uhr K(1), Prager-van der Smissen WJC(1), Heine...   \n",
       "\n",
       "                                                    3  \\\n",
       "0   Author information:\\n(1)Department of Hematolo...   \n",
       "1   Author information:\\n(1)Department of Experime...   \n",
       "2   Author information:\\n(1)Guangzhou Medical Univ...   \n",
       "3   Author information:\\n(1)Department of Cell and...   \n",
       "4   Author information:\\n(1)Department of Neurosur...   \n",
       "5   Author information:\\n(1)Faculty of Engineering...   \n",
       "6   Author information:\\n(1)Department of Hematolo...   \n",
       "7   Author information:\\n(1)Department of Hematolo...   \n",
       "8   Author information:\\n(1)Department of Hematolo...   \n",
       "9   Author information:\\n(1)Department of Human Pa...   \n",
       "10  Author information:\\n(1)Department of Hematolo...   \n",
       "11  Author information:\\n(1)Department of Thoracic...   \n",
       "12  Author information:\\n(1)Department of Biomedic...   \n",
       "13  Author information:\\n(1)Department of Hematolo...   \n",
       "14  Author information:\\n(1)Department of Hematolo...   \n",
       "15  Author information:\\n(1)Department of Hematolo...   \n",
       "16  Author information:\\n(1)Department of Biochemi...   \n",
       "17  Author information:\\n(1)Department of Hematolo...   \n",
       "18  Author information:\\n(1)Department of Hematolo...   \n",
       "19  Author information:\\n(1)Department of Laborato...   \n",
       "20  Author information:\\n(1)Department of Hematolo...   \n",
       "21  Author information:\\n(1)Department of Hematolo...   \n",
       "22  Author information:\\n(1)Orthopaedics Departmen...   \n",
       "23  Author information:\\n(1)Department of Experime...   \n",
       "24  Author information:\\n(1)The Third Xiangya Hosp...   \n",
       "25  Author information:\\n(1)Department of Laborato...   \n",
       "26  Author information:\\n(1)Dept. of Laboratory He...   \n",
       "27  Author information:\\n(1)a Department of Hemato...   \n",
       "28  Author information:\\n(1)School of Clinical Med...   \n",
       "29  Author information:\\n(1)Department of Medical ...   \n",
       "\n",
       "                                                    4  \\\n",
       "0   Despite advances in multiple myeloma (MM) trea...   \n",
       "1   G protein-coupled estrogen receptor 1 (GPER1) ...   \n",
       "2   Bone marrow stromal cell (BMSC)-derived small ...   \n",
       "3   The miR-200b/429 located at 1p36 is a highly c...   \n",
       "4   The microRNAs (miRNAs), an extensive class of ...   \n",
       "5   Multiple myeloma is a hematological cancer typ...   \n",
       "6   BACKGROUND: Bortezomib resistance hampers the ...   \n",
       "7   Circular RNAs (circRNAs) have been shown to pl...   \n",
       "8   OBJECTIVE: Long non-coding RNA ANGPTL1-3 (lnc-...   \n",
       "9   Circular RNAs (circRNAs) are a novel type of c...   \n",
       "10  OBJECTIVE: This study investigated the mechani...   \n",
       "11  INTRODUCTION: Changes in microRNAs (miRs) cont...   \n",
       "12  Multiple myeloma (MM) progression and drug res...   \n",
       "13  Multiple myeloma (MM) is a malignant cancer wi...   \n",
       "14  Multiple myeloma is a frequent hematologic mal...   \n",
       "15  Multiple myeloma (MM) is a common malignant he...   \n",
       "16  INTRODUCTION: Multiple myeloma (MM) remains an...   \n",
       "17  Multiple myeloma (MM) is a malignant neoplasm ...   \n",
       "18  The bone marrow microenvironment plays an esse...   \n",
       "19  The mechanisms of drug resistance in multiple ...   \n",
       "20  The overall survival of multiple myeloma (MM) ...   \n",
       "21  Circular RNAs (circRNAs) possess important reg...   \n",
       "22  AIMS: Bortezomib (BTZ) is described as the fir...   \n",
       "23  Bortezomib is the first-in-class proteasome in...   \n",
       "24  BACKGROUND: It has been demonstrated that circ...   \n",
       "25  Overexpression of Myristoylated Alanine-Rich C...   \n",
       "26  BACKGROUND: Multiple myeloma (MM) cells gain p...   \n",
       "27  Background: Nowadays, microRNAs (miRNAs) attra...   \n",
       "28  Multiple Myeloma (MM) is a malignant hematolog...   \n",
       "29  MicroRNAs (miRNAs) regulate gene expression po...   \n",
       "\n",
       "                                                    5  \\\n",
       "0   DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...   \n",
       "1   DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...   \n",
       "2   DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...   \n",
       "3                              © 2023. The Author(s).   \n",
       "4   Copyright © 2023 The Authors. Published by Els...   \n",
       "5   DOI: 10.3390/ph16010111\\nPMCID: PMC9864669\\nPM...   \n",
       "6   Copyright © 2022 The Authors. Published by Els...   \n",
       "7   Copyright © 2022 Wolters Kluwer Health, Inc. A...   \n",
       "8   DOI: 10.1080/16078454.2022.2072062\\nPMID: 3561...   \n",
       "9   DOI: 10.3390/cancers14071700\\nPMCID: PMC899705...   \n",
       "10  Copyright © 2022 Elsevier Ltd. All rights rese...   \n",
       "11                        © 2022 S. Karger AG, Basel.   \n",
       "12  © 2021 The Pathological Society of Great Brita...   \n",
       "13  Copyright © 2021 Lai, Huang, Nie, Chen, Tang, ...   \n",
       "14  Copyright © 2021 Wolters Kluwer Health, Inc. A...   \n",
       "15  Copyright© Bentham Science Publishers; For any...   \n",
       "16                     © 2021 Rodrigues-Junior et al.   \n",
       "17                     © 2020 Wiley Periodicals, Inc.   \n",
       "18  © 2021 The Authors. Cell Biology International...   \n",
       "19  DOI: 10.3324/haematol.2019.227579\\nPMCID: PMC7...   \n",
       "20  Copyright © 2020 Elsevier B.V. All rights rese...   \n",
       "21  DOI: 10.1080/15384101.2020.1839701\\nPMCID: PMC...   \n",
       "22  Copyright © 2020 Elsevier Inc. All rights rese...   \n",
       "23  DOI: 10.3390/cancers12092569\\nPMCID: PMC756585...   \n",
       "24                                  © 2020 Liu et al.   \n",
       "25  Copyright © 2020 Elsevier B.V. All rights rese...   \n",
       "26  DOI: 10.1186/s12885-019-6151-x\\nPMCID: PMC6805...   \n",
       "27  DOI: 10.1080/15384101.2019.1632138\\nPMCID: PMC...   \n",
       "28  Copyright © 2019 Elsevier Inc. All rights rese...   \n",
       "29  DOI: 10.1371/journal.pone.0216400\\nPMCID: PMC6...   \n",
       "\n",
       "                                                    6  \\\n",
       "0                                                None   \n",
       "1   Conflict of interest statement: The authors de...   \n",
       "2                                                None   \n",
       "3   DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...   \n",
       "4   DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...   \n",
       "5   Conflict of interest statement: The authors de...   \n",
       "6   DOI: 10.1016/j.leukres.2022.106967\\nPMID: 3627...   \n",
       "7   DOI: 10.1097/CAD.0000000000001378\\nPMID: 36136...   \n",
       "8                                                None   \n",
       "9   Conflict of interest statement: The authors de...   \n",
       "10  DOI: 10.1016/j.leukres.2022.106785\\nPMID: 3507...   \n",
       "11  DOI: 10.1159/000518936\\nPMID: 35042223 [Indexe...   \n",
       "12  DOI: 10.1002/path.5852\\nPMID: 34919276 [Indexe...   \n",
       "13  DOI: 10.3389/fonc.2021.720261\\nPMCID: PMC84930...   \n",
       "14  DOI: 10.1097/CAD.0000000000001166\\nPMID: 34387...   \n",
       "15  DOI: 10.2174/0929867328666210504104419\\nPMID: ...   \n",
       "16  DOI: 10.2147/OTT.S286751\\nPMCID: PMC7814994\\nP...   \n",
       "17  DOI: 10.1002/jcb.29684\\nPMID: 33417267 [Indexe...   \n",
       "18  DOI: 10.1002/cbin.11540\\nPMCID: PMC8248034\\nPM...   \n",
       "19                                               None   \n",
       "20  DOI: 10.1016/j.ejphar.2020.173752\\nPMID: 33253...   \n",
       "21  Conflict of interest statement: The authors ha...   \n",
       "22  DOI: 10.1016/j.lfs.2020.118506\\nPMID: 33031827...   \n",
       "23  Conflict of interest statement: The authors de...   \n",
       "24  DOI: 10.2147/CMAR.S241089\\nPMCID: PMC7094164\\n...   \n",
       "25  DOI: 10.1016/j.canlet.2020.03.020\\nPMID: 32220...   \n",
       "26  Conflict of interest statement: The authors de...   \n",
       "27                                               None   \n",
       "28  DOI: 10.1016/j.bbrc.2019.05.078\\nPMID: 3110326...   \n",
       "29  Conflict of interest statement: I have read th...   \n",
       "\n",
       "                                                    7  \\\n",
       "0                                                None   \n",
       "1                                                None   \n",
       "2                                                None   \n",
       "3   Conflict of interest statement: The authors de...   \n",
       "4   Conflict of interest statement: Conflict of In...   \n",
       "5                                                None   \n",
       "6   Conflict of interest statement: Declaration of...   \n",
       "7                                                None   \n",
       "8                                                None   \n",
       "9                                                None   \n",
       "10                                               None   \n",
       "11                                               None   \n",
       "12                                               None   \n",
       "13  Conflict of interest statement: The authors de...   \n",
       "14                                               None   \n",
       "15                                               None   \n",
       "16  Conflict of interest statement: Maria Aparecid...   \n",
       "17                                               None   \n",
       "18  Conflict of interest statement: The authors de...   \n",
       "19                                               None   \n",
       "20                                               None   \n",
       "21                                               None   \n",
       "22                                               None   \n",
       "23                                               None   \n",
       "24  Conflict of interest statement: The authors re...   \n",
       "25  Conflict of interest statement: Declaration of...   \n",
       "26                                               None   \n",
       "27                                               None   \n",
       "28                                               None   \n",
       "29                                               None   \n",
       "\n",
       "                                                  doi  \n",
       "0   DOI: 10.1080/10428194.2023.2278431\\nPMID: 3794...  \n",
       "1   DOI: 10.3390/cells12182226\\nPMCID: PMC10526814...  \n",
       "2   DOI: 10.1158/0008-5472.CAN-23-0189\\nPMID: 3775...  \n",
       "3   DOI: 10.1007/s10528-023-10356-2\\nPMCID: PMC105...  \n",
       "4   DOI: 10.1016/j.biopha.2023.114432\\nPMID: 36841...  \n",
       "5   DOI: 10.3390/ph16010111\\nPMCID: PMC9864669\\nPM...  \n",
       "6   DOI: 10.1016/j.leukres.2022.106967\\nPMID: 3627...  \n",
       "7   DOI: 10.1097/CAD.0000000000001378\\nPMID: 36136...  \n",
       "8   DOI: 10.1080/16078454.2022.2072062\\nPMID: 3561...  \n",
       "9   DOI: 10.3390/cancers14071700\\nPMCID: PMC899705...  \n",
       "10  DOI: 10.1016/j.leukres.2022.106785\\nPMID: 3507...  \n",
       "11  DOI: 10.1159/000518936\\nPMID: 35042223 [Indexe...  \n",
       "12  DOI: 10.1002/path.5852\\nPMID: 34919276 [Indexe...  \n",
       "13  DOI: 10.3389/fonc.2021.720261\\nPMCID: PMC84930...  \n",
       "14  DOI: 10.1097/CAD.0000000000001166\\nPMID: 34387...  \n",
       "15  DOI: 10.2174/0929867328666210504104419\\nPMID: ...  \n",
       "16  DOI: 10.2147/OTT.S286751\\nPMCID: PMC7814994\\nP...  \n",
       "17  DOI: 10.1002/jcb.29684\\nPMID: 33417267 [Indexe...  \n",
       "18  DOI: 10.1002/cbin.11540\\nPMCID: PMC8248034\\nPM...  \n",
       "19  DOI: 10.3324/haematol.2019.227579\\nPMCID: PMC7...  \n",
       "20  DOI: 10.1016/j.ejphar.2020.173752\\nPMID: 33253...  \n",
       "21  DOI: 10.1080/15384101.2020.1839701\\nPMCID: PMC...  \n",
       "22  DOI: 10.1016/j.lfs.2020.118506\\nPMID: 33031827...  \n",
       "23  DOI: 10.3390/cancers12092569\\nPMCID: PMC756585...  \n",
       "24  DOI: 10.2147/CMAR.S241089\\nPMCID: PMC7094164\\n...  \n",
       "25  DOI: 10.1016/j.canlet.2020.03.020\\nPMID: 32220...  \n",
       "26  DOI: 10.1186/s12885-019-6151-x\\nPMCID: PMC6805...  \n",
       "27  DOI: 10.1080/15384101.2019.1632138\\nPMCID: PMC...  \n",
       "28  DOI: 10.1016/j.bbrc.2019.05.078\\nPMID: 3110326...  \n",
       "29  DOI: 10.1371/journal.pone.0216400\\nPMCID: PMC6...  "
      ]
     },
     "execution_count": 286,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 288,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{0: 'Leuk Lymphoma. 2023 Nov 10:1-8. doi: 10.1080/10428194.2023.2278431. Online\\nahead  of print.',\n",
       " 1: 'Cells. 2023 Sep 7;12(18):2226. doi: 10.3390/cells12182226.',\n",
       " 2: 'Cancer Res. 2023 Sep 26. doi: 10.1158/0008-5472.CAN-23-0189. Online ahead of \\nprint.',\n",
       " 3: 'Biochem Genet. 2023 Oct;61(5):1898-1916. doi: 10.1007/s10528-023-10356-2. Epub\\n 2023 Mar 7.',\n",
       " 4: 'Biomed Pharmacother. 2023 May;161:114432. doi: 10.1016/j.biopha.2023.114432. \\nEpub 2023 Feb 24.',\n",
       " 5: 'Pharmaceuticals (Basel). 2023 Jan 12;16(1):111. doi: 10.3390/ph16010111.',\n",
       " 6: 'Leuk Res. 2022 Dec;123:106967. doi: 10.1016/j.leukres.2022.106967. Epub 2022\\nOct  6.',\n",
       " 7: 'Anticancer Drugs. 2022 Oct 1;33(9):893-902. doi: 10.1097/CAD.0000000000001378.\\n Epub 2022 Sep 14.',\n",
       " 8: 'Hematology. 2022 Dec;27(1):596-602. doi: 10.1080/16078454.2022.2072062.',\n",
       " 9: 'Cancers (Basel). 2022 Mar 27;14(7):1700. doi: 10.3390/cancers14071700.',\n",
       " 10: 'Leuk Res. 2022 Mar;114:106785. doi: 10.1016/j.leukres.2022.106785. Epub 2022\\nJan  7.',\n",
       " 11: 'Chemotherapy. 2022;67(2):110-122. doi: 10.1159/000518936. Epub 2022 Jan 18.',\n",
       " 12: 'J Pathol. 2022 Apr;256(4):402-413. doi: 10.1002/path.5852. Epub 2022 Jan 21.',\n",
       " 13: 'Front Oncol. 2021 Sep 22;11:720261. doi: 10.3389/fonc.2021.720261. eCollection\\n 2021.',\n",
       " 14: 'Anticancer Drugs. 2022 Jan 1;33(1):e145-e154. doi:\\n10.1097/CAD.0000000000001166.',\n",
       " 15: 'Curr Med Chem. 2021 Oct 25;28(33):6753-6772. doi: \\n10.2174/0929867328666210504104419.',\n",
       " 16: 'Onco Targets Ther. 2021 Jan 15;14:455-467. doi: 10.2147/OTT.S286751.\\neCollection  2021.',\n",
       " 17: 'J Cell Biochem. 2021 Apr;122(3-4):305-314. doi: 10.1002/jcb.29684. Epub 2021\\nJan  8.',\n",
       " 18: 'Cell Biol Int. 2021 May;45(5):965-975. doi: 10.1002/cbin.11540. Epub 2021 Jan \\n15.',\n",
       " 19: 'Haematologica. 2020 Dec 1;105(12):2813-2823. doi:\\n10.3324/haematol.2019.227579.',\n",
       " 20: 'Eur J Pharmacol. 2021 Jan 15;891:173752. doi: 10.1016/j.ejphar.2020.173752.\\nEpub  2020 Nov 28.',\n",
       " 21: 'Cell Cycle. 2020 Dec;19(23):3289-3302. doi: 10.1080/15384101.2020.1839701.\\nEpub  2020 Nov 1.',\n",
       " 22: 'Life Sci. 2020 Dec 1;262:118506. doi: 10.1016/j.lfs.2020.118506. Epub 2020 Oct\\n 5.',\n",
       " 23: 'Cancers (Basel). 2020 Sep 9;12(9):2569. doi: 10.3390/cancers12092569.',\n",
       " 24: 'Cancer Manag Res. 2020 Mar 20;12:2109-2118. doi: 10.2147/CMAR.S241089. \\neCollection 2020.',\n",
       " 25: 'Cancer Lett. 2020 Jun 28;480:29-38. doi: 10.1016/j.canlet.2020.03.020. Epub\\n2020  Mar 24.',\n",
       " 26: 'BMC Cancer. 2019 Oct 21;19(1):975. doi: 10.1186/s12885-019-6151-x.',\n",
       " 27: 'Cell Cycle. 2019 Jul;18(14):1660-1669. doi: 10.1080/15384101.2019.1632138.\\nEpub  2019 Jun 20.',\n",
       " 28: 'Biochem Biophys Res Commun. 2019 Jul 5;514(4):1140-1146. doi: \\n10.1016/j.bbrc.2019.05.078. Epub 2019 May 15.',\n",
       " 29: 'PLoS One. 2019 May 7;14(5):e0216400. doi: 10.1371/journal.pone.0216400. \\neCollection 2019.'}"
      ]
     },
     "execution_count": 288,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.to_dict()[0]"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
